



ERS

EUROPEAN RESPIRATORY SOCIETY

VIENNA 2012

ANNUAL CONGRESS **austria, 1-5 september**

**PREPARE YOUR
CONGRESS**
Advance Programme

| PRACTICAL INFORMATION

REGISTRATION INFORMATION

Online registration

www.erscongress2012.org/registration

The deadline for online registration is **August 31st 2012 at 20:00 CET**.

Registrations and payments made on or after September 1st 2012 are based on the onsite fees.

Pre- registration

K.I.T. Group must receive the registration form and payment—by bank transfer or credit card—by 21st July 2012 at 24:00 CET. After this date, payment is only by credit card.

Badges, vouchers, etc

Pre-registered delegates receive their badges and vouchers in advance by mail. They are requested to bring the badge and vouchers with them to the Congress Centre.

Delegates registered on or after 22nd July 2012 must collect their badges and other material onsite in the Congress registration area.

Congress bag

The Congress bag will be available, on a first come first served basis, in Hall A of the Congress Center.

Public Transport Pass (Wiener Linien)

Vienna offers an extensive travel network by underground, tram and bus. The complimentary Wiener Linien ticket, which is included in the registration fee, will allow free use on all Wiener Linien means of transport through the city within the Congress period September 1-5 2012.

Except to/ from the airport, CAT tickets can be obtained directly at the CAT counter at the airport terminal or at City Air Terminal (Wien Mitte).

Registration opening hours

Day	Date	Opens	Closes
Saturday	September 1st	07:00	18:15
Sunday	September 2nd	07:00	17:30
Monday	September 3rd	06:30	17:30
Tuesday	September 4th	06:30	17:30
Wednesday	September 5th	07:00	14:00

All timings are subject to change.

Registration fee (See next page)

All registration fees should be paid in advance in Euro (€) and made out to K.I.T. Group, with the mention "ERS 2012". **Do not forget to indicate your first and last name on the payment.**

The registration fee includes:

- Access to all Scientific sessions and Congress Exhibition;
- Access to the Abstract Print Zone;

- Congress bag (first come first served basis)
- Congress badge;
- Congress Programme;
- Public transport pass (valid from Saturday September 1st to Wednesday September 5th)

Note: The registration fee does not include Postgraduate Courses, "Meet the Professor" seminars, Morning Seminars and the Primary Care Day.

Accepted modes of payment

1. Bank Transfer

Account Holder: K.I.T. Swiss AG

Case Postale

CH – 1211 Geneva 2, Switzerland

Clearing No: 240

Bank: UBS SA

Account No: 240-739508.61Q

Swift: UBSWCHZH80A

IBAN: CH 81 0024 0240 7395 0861 Q

Please indicate "free of charge for the receiver account" and give your full name and registration number.

2. Credit card

Visa, Eurocard/Mastercard credit card payments are only accepted up to €1,500. Credit cards are debited in Euro (€).

3. Cheques

Payment to K.I.T. Group by company cheque only.

Personal cheques and Eurocheques are not accepted.

Cheques should be mailed to:

ERS 2012 c/o K.I.T. Group GmbH

Association & Conference Management

Kurfürstendamm 71

D-10709 Berlin

Germany

Cancellation

Cancellation of registration can be made up to 21 July 2012 - midnight CET.

Notification of the cancellations must be sent in writing to K.I.T Group: ers2012registration@kit-group.org. Refunds of registrations fees will be made after the Congress, minus a 25% administration charge. **There will be no refund for cancelations made after 21 July 2012.**

Confirmation

On receipt of a completed registration form and correct fee, each participant will receive electronic confirmation of their registration. An individual email address must be provided.

Single day tickets

Single day tickets are available for purchase at the Congress Centre only.

Name changes

Individuals may make name changes only in exceptional cases, at a cost of EUR 35. Written permission from the original participant will be required in order to process an individual name change.

Sponsors who wish to make name changes will be charged a handling fee of EUR 35 per name change. A new registration from each replacement will be required before the name change can be processed.

Name changes (for individuals or groups) will be accepted by mail or by fax by K.I.T. Group: ers2012registration@kit-group.org until the pre-registration deadline of 20 August 2012. After this date, they must be done on site in Vienna.

Letters for visa application

Official letters to resolve difficulties encountered in certain countries with visa applications will be provided upon request **only to delegates whose registration and payment have been confirmed.**

Requests should be made to ersletter@kit-group.org before 27 August 2012.

Certificates of attendance

Certificates of attendance are available to delegates only; they can be printed onsite at the self service facilities at the end of the Congress or through the Congress Website:

www.erscongress2012.org after the Congress. Please use the digit code shown on your badge.

Italian delegates

The official agency for Italian delegates is:

Dr.ssa Annalisa Ramazzotti

Via D. Niccodemi, 14

I-20052 Monza (MI)

Tel/Fax: +390 39 212 1693

ipcra@libero.it

Registration fees

Registration fees 2012 (€) Vienna These prices and dates are indicative and may be subject to change	Paid up to June 18, 2012	Paid from June 19, 2012	From August 31, 2012
	24:00 CET		18:00 CET
Fees	Early Bird	Standard	On-site
Full rate	550	685	735

Special Categories

Gold Registration Pack is now available to NEW, SILVER and Renewing Gold Members If you request paper copies of publications and come from non EU-Countries, an 25 Euros postal charges will be added"	575	730	780
ERS Gold Member	405	560	610
Under 35, Allied Health Professional, Scientist (PhD, non-MD)	220	345	395
"Allied Health Professional 2-day package ¹	265	380	430

¹ Valid for Saturday 1 and Sunday 2, only, including 1 PG of your choice.

Additional Courses (not included in the registration fee)	Early Bird Fee	Standard fee	On-site Fee
Postgraduate Courses*	90	120	120
Full Day Course	150	180	180
"Meet the Professor" Seminars	65	85	85
Morning Seminars	65	85	85

*Delegates attending Postgraduate Courses only and NOT the ERS Congress will pay a single additional €25 handling fee.

Primary Care day Only (not included in the registration fee)	Early Bird Fee	Standard fee	On-site Fee
ERS Member and/or Allied Health Professional	50	50	60
Non ERS Member	80	80	100

GENERAL INFORMATION (A-Z)



Congress Venue

Reed Messe Wien GmbH
 Messeplatz 1
 Postfach 277
 A-1021 Wien
 T +43 (0)1 727 20-0
 F +43 (0)1 727 20-2359
 E congress@messe.at
 www.messecongress.at

Children and Accompanying Persons

Children and members of the public are not permitted in the exhibition area or any room hosting an industry activity. In addition, the ERS asks delegates and faculty to refrain from taking children and accompanying adults to any scientific sessions or practical demonstrations. In the event that children are required to enter the Congress Centre they should be supervised by an adult at all times and observe the restrictions that apply to limited access areas. In the event that a member of public is invited to participate in the ERS Congress scientific programme, they should be accompanied by a qualified healthcare professional or ERS representative observing the ERS restrictions where appropriate.

Cloakroom

A cloakroom service for coats and reasonably sized luggage is available during the opening hours of the Congress

Data scanning system

Congress badges will contain a barcode—acting as an electronic business card—to enable visitors to leave their contact details for exhibitors quickly and easily.

Dress code

Dress will be informal throughout the Congress. ERS reserves the right to refuse access when deemed necessary for the comfort and safety of all delegates.

ERS Congress Final Programme APP.

Sponsored by Novartis



The ERS Annual Congress Final Programme will be available for the second time as an interactive Smartphone app compatible with iPhone and android devices. The app can be downloaded from August onwards, free of charge, via the Vienna Congress Website. It will allow you to plan your congress, search by room, time, speaker, disease group, etc. and has also practical info such as floor plans and exhibitor lists. The ERS Congress smartphone application will also allow you this year to download some companies' activities and add it directly to your agenda.

Dates and opening hours

	Congress Centre	Registration	Speakers' Preview Room	ERS Sessions	Evening Symposia	Exhibition
Saturday, September 1	07:00–21:00	07:00–18:15	07:30–17:30	09:30–17:30**		
Sunday, September 2	07:00–19:30	07:00–17:30	07:30–17:30	08:30–16:45	17:15–19:15	09:00–17:00
Monday, September 3	06:30–19:30	06:30–17:30	07:30–17:30	07:00–16:45	17:15–19:15	09:00–17:00
Tuesday, September 4	06:30–19:30	06:30–17:30	07:30–17:30	07:00–16:45	17:15–19:15	09:00–17:00
Wednesday, September 5	07:00–13:30*	07:00–14:00	08:00–11:00	08:30–12:45		09:00–12:00

* No afternoon sessions

** Postgraduates Courses only

All timings are subject to change.



ERS Connect

Free WiFi sponsored by Mundipharma



Congress delegates will have free access to the Internet throughout the Congress Centre via ERS Connect. Delegates without WiFi enabled devices can access the internet using the free standing internet pods or by using the connection cables at the workstations both of which being located in the ERS Connect area in the centre of the Exhibition Hall. Free WiFi login information can be found on posters situated around the Congress Centre or on the flyer in the Congress bag.

Hotel Desk

A Hotel Desk will be available in the ERS Registration Area from Saturday 1 September to Wednesday 5 September 2012, during Congress opening hours.

Insurance and disclaimer

ERS accepts no liability for injuries and/or losses of whatever nature incurred by participants and/or accompanying persons, nor for loss or damage to their luggage and/or personal belongings. Please check the validity of your own insurance.

Language

The official language of the Congress is English. No translation will be provided.

Lunch and refreshments

No official meals will be provided. Meal facilities at the Congress centre include cafeterias and restaurants. A number of bars and coffee/snack points serve sandwiches and snacks.

Smoking

As smoking is a major cause of lung disease, ERS further asks Congress participants and exhibitors not to smoke in the Reed Messe Wien or any area.

Special accessibility needs

If you require special arrangements to participate fully in the Congress, please contact:

Reed Messe Wien GmbH

Messeplatz 1
Postfach 277
A-1021 Wien
T +43 (0)1 727 20-0
F +43 (0)1 727 20-2359
info@messe.at

Taxis

The following taxi companies can offer their services

- WIHUP Taxiservice: +43 (0) 1 601 60
- Taxifunkzentrale: +43 (0) 1 401 00
- Taxi 31300 VermittlungsgmbH: +43 (0) 1 313 00

Tourist information

www.wien.info

TRAVEL INFORMATION

Star Alliance™: official airline of the ERS Vienna 2012 Congress.

Arrival at Vienna International Airport

Vienna's main international airport is only 15 km (around 20 minutes) away from the city centre.

From the airport there are several ways to travel to Vienna city centre:

1. Train (CAT)

The most comfortable way to get to the city from the airport is the non-stop City Airport Train (CAT) direct to the City Air Terminal (Wien Mitte) within 16 minutes, departing every 30 minutes for both ways. From here you can continue your trip with the underground. The cost of the journey one way is € 10,00.

2. Bus

You can take the frequent bus connection to the city center as well. Take the bus (Vienna Airport Lines) to "Schwedenplatz" (where the underground lines U1 and U4 stop). The Vienna Airport Lines buses leave from the airport (outside the arrivals) and take about 20 minutes to reach the city center. The fare for a single ticket to the city centre is € 7.00.

3. Taxi

Taxis are available in front of the airport arrival building. A taxi from the Airport to the city centre costs approximately € 33 per trip and takes about 20 minutes.

For more information, please visit the Vienna Airport Website: <http://www.viennaairport.com>

Public transport pass (Wiener Linien)

Vienna offers an extensive travel network by underground, tram and bus. The complimentary Wiener Linien ticket is included in the registration fee and will be printed on your Congress Badge.

This transport ticket will allow free use on all Wiener Linien means of transport through the city within the Congress period September 1-5 2012, except to/ from the airport. To reach the airport, CAT tickets can be purchased directly at the CAT counter at the airport terminal or at City Air Terminal (Wien Mitte). The cost of the journey one way is € 10,00.

Arrival in Vienna by train

In Vienna there are two major train stations. There is the train station west (Westbahnhof) and the train station south (Südbahnhof). From both stations you have access to the underground lines to get to the city centre.

How to get to the Congress Centre

Reed Messe Wien Exhibition & Congress Centre

From city centre, there are three ways to reach Reed Messe Wien:

1. Underground (U-Bahn)

This is the most convenient way to reach the Messe Wien: the U2 underground line in the "Stadion" direction from the city centre will take you to the station "Messe Prater", located just opposite the entrance of the Congress Center.

2. Car

Once you reach the motorways surrounding Vienna, take the "Stadt-Autobahn", the A23 motorway and exit at "Handelskai / Messezentrum". Parking facilities for more than 4'000 vehicles are conveniently located close to the Messe Wien.

3. Taxis

From the city centre (State Opera) a taxi can bring you in approximately 15 minutes to the Messe Wien. The cost of the ride would be approximately € 15.00 - €20.00.

Departure for Vienna International Airport

The easiest way to reach the airport is taking the City Air Train (CAT) from the City Air Terminal. From the Congress Center:

1. Underground (U-Bahn)

Take U2 direction "Karlsplatz" and get off at "Schottenring", then take U4 direction "Hütteldorf" and get off at "Landstrasse" (Wien Mitte). Once there, just follow the CAT signage.

2. Underground (U-Bahn) and Commuter train (S-Bahn)

Take U2 direction "Karlsplatz" and get off at "Praterstern". Then take the commuter train (S-Bahn) one stop to "Landstrasse". Once there, just follow the CAT signage.

SAVE UP TO 20% ON TRAVEL WITH THE STAR ALLIANCE™ NETWORK

The Star Alliance member airlines are pleased to be appointed as the Official Airline Network for European Respiratory Society Congress.

To obtain the Star Alliance Conventions Plus discounts please follow the below steps to access the Conventions Plus online booking tool:

- Visit www.staralliance.com/conventionsplus/delegates/
- Under “Delegates login” enter conventions code OS03A16.
- The online booking tool opens in a separate window*

*Should the online booking tool not open, please ensure that your Pop-Up blocker is disabled.

Registered participants plus one accompanying person travelling to the event can qualify for a discount of up to 20%, depending on fare and class of travel booked.


The participating airlines for this event are: Air Canada, bmi, Air China, Continental Airlines, Ethiopian Airlines, TAM Airlines, Adria Airways, Lufthansa, LOT Polish Airlines, SWISS International Air Lines, EgyptAir, ANA, Austrian Airlines, Croatia Airlines, Asiana Airlines, Scandinavian Airlines, Brussels Airlines, Turkish Airlines, TAP Portugal, United.

Discounts are offered on most published **business** and **economy class** fares, excluding website/internet fares, senior and youth fares, group fares and Round the World fares.

Please note: For travel to/from Japan and New Zealand special fares or discounts may be offered by the participating airlines on their own network. To obtain these special fares or discounts and for booking office information please visit www.staralliance.com/conventionsplus/delegates/ and:

- Click on “Conventions Plus Booking Contacts” and enter the conventions code OS03A16.
- Choose one of the participating airlines listed
- Call the respective reservation contact listed and quote the conventions code OS03A16 when requesting the special ticket

When making your travel plans please present confirmation of your registration or proof of attendance for the Event/Convention.



This information is dated of 11 April 2012. Visit www.erscongress2012.org for updates.

SCIENTIFIC PROGRAMME OVERVIEW

Running from Sunday, 2 September 2012 (08:30) to Wednesday, 5 September 2012 (12:45), the Scientific Programme is highly comprehensive and addresses the latest advances in clinical diagnosis and treatment of lung disease.

It comprises over 60 Symposia, Year in Reviews, Hot Topics and Grand Rounds, as well as some 260 Free Communication sessions, including Oral Presentations, Poster Discussions and Thematic Posters, and a series of Evening Symposia, Evening Mini-Symposia, Evening Expert Forums and Practical

Workshops organised by industry. A regularly updated version of the Scientific Programme, including a day-by-day guide to sessions, is available online at www.erscongress2012.org.

ERS has received an important number of abstract submissions, with a total of 5,185 abstracts submitted for the 2012 Annual Congress. These will be considered for the Free Communication sessions and will be presented as Oral Presentations, Thematic Posters and Poster Discussions.

SUNDAY 2 SEPTEMBER		TYPE
08:30-10:30	Award for Achievement in the field of NSCLC Ceremony (supported by AstraZeneca) followed by Grand Round "How to diagnose and manage NSCLC with the new drugs" - an interactive session	Grand Round
08:30-10:30	Pulmonary injury and repair from alveolus to vessel walls	Symposium
08:30-10:30	Pro-Con Debate "Severe community-acquired pneumonia: a lung disease?"	Symposium
08:30-10:30	An Olympic challenge: winners and losers in exercise training	Symposium
08:30-10:30	Asthma from childhood to adulthood: what factors predict the outcome?	Symposium
08:30-10:30	Respiratory support in children and young adults with neuromuscular disease	Hot Topic
08:30-10:30	New advances in ICU-acquired weakness	Symposium
10:45-12:45	Cournand Lecture followed by Hot Topic on "Early intervention in CF: why, when and how?"	Cournand Lecture
10:45-12:45	Current challenges in multimodality lung cancer treatment	Symposium
10:45-12:45	Brian Whipp Memorial Symposium "Cardio-pulmonary exercise physiology: from olympic gold to clinical goals"	Hot Topic
10:45-12:45	Cochrane reviews in airway diseases	Symposium
10:45-12:45	Prevention and treatment of infective exacerbations of COPD	Symposium
10:45-12:45	Searching for the secrets of senescence in the lung	Hot Topic
10:45-12:45	Paediatric lung function today	Symposium
14:45-16:45	Imaging Grand Round - an interactive session	Grand Round
14:45-16:45	Unimodal treatment for non-small cell lung cancer: dawn of a renaissance?	Symposium
14:45-16:45	COPD and OSA: two prevalent diseases related to cardiovascular disease by common mechanism?	Symposium
14:45-16:45	An ERS/ELF joint symposium "New tools to assess improvement in respiratory patients: capturing the patient's perspective"	Symposium
14:45-16:45	Viral respiratory disease in preschool children	Symposium
14:45-16:45	Autoimmunity in airways disease	Symposium
14:45-16:45	Reclassification of idiopathic interstitial pneumonias	Symposium
17:15-19:15	Predicting and Preventing Future Risk in COPD; <i>Organised by Takeda Pharmaceuticals International</i>	Evening Symposium
17:15-19:15	Innovation for individualisation: Applying the science to the patient; <i>Organised by GlaxoSmithKline</i>	Evening Symposium
17:15-19:15	Balancing benefit and risk: new developments in the treatment of PAH; <i>Organised by Novartis Pharma AG</i>	Evening Symposium
17:15-19:15	Pneumonias in obstructive lung disease; <i>Organised by AstraZeneca</i>	Evening Symposium
17:15-19:15	Combination bronchodilators: the preferred treatment for COPD?; <i>Organised by Boehringer Ingelheim</i>	Evening Symposium

BASIC

CLINICAL

EPIDEMIOLOGY/
ENVIRONMENT

INFECTION

INTENSIVE
CARE

ONCOLOGY

PAEDIATRIC

PHYSIOLOGY

SLEEP

17:15-19:15	“Is it good enough?” - A debate on treatment response in pulmonary arterial hypertension; <i>Organised by Actelion</i>	Evening Symposium
17:15-19:15	Managing patients with IPF in a new era; <i>Organised by InterMune International AG</i>	Evening Symposium
17:15-19:15	Lower Respiratory Tract Infections: managing patients at risk of poor outcomes; <i>Organised by Bayer HealthCare Pharmaceuticals</i>	Evening Symposium
17:15-19:15	Prevention of Exacerbations in COPD: Expanding Scope and Strategies; <i>Organised by OM Pharma Ltd</i>	Evening Symposium
17:15-19:15	Personalized Medicine: Treatment Advances and the Genetic Medicine Revolution; <i>Organised by Vertex Pharmaceuticals</i>	Evening Symposium
17:15-19:15	COPD and AATD - Why do we miss so many patients?; <i>Organised by Grifols International SA</i>	Evening Symposium
17:30-19:00	PneumRx Lung Volume Reduction Coil; <i>Organised by PneumRx</i>	Evening Mini Symposium
17:30-19:00	Optimal management of pulmonary arterial hypertension patients: Are we there yet? - A case-based approach; <i>Organised by Pfizer Ltd</i>	Evening Mini Symposium

MONDAY 3 SEPTEMBER			
08:30-10:30	Paediatric Grand Round - an interactive session	Grand Round	
08:30-10:30	Treatment of tobacco dependence as a treatment of lung diseases	Symposium	
08:30-10:30	Fighting MDR- and XDR-TB in Europe: from programme results to research implementation	Symposium	
08:30-10:30	Lung transplantation in 2012: where are we?	Symposium	
08:30-10:30	Treatment of paediatric sleep-disordered breathing in special populations	Symposium	
08:30-10:30	Are neutrophils a suitable target in severe asthma?	Symposium	
10:45-12:45	The global burden of disease	Hot Topic	
10:45-12:45	Antenatal origins of chronic respiratory disease: putting the fetal origins hypothesis to the test	Symposium	
10:45-12:45	Advances in chronic respiratory failure in COPD: now out of its infancy	Symposium	
10:45-12:45	Endo meets obstruction: the new endoscopic treatment options for obstructive lung diseases	Symposium	
10:45-12:45	Supportive and palliative care in the management of the patient with a thoracic malignancy	Symposium	
10:45-12:45	Functional pulmonary imaging for COPD phenotyping	Symposium	
10:45-12:45	Acute lung injury: challenging old paradigms	Symposium	
14:45-16:45	Ethics Grand Round - an interactive session	Grand Round	
14:45-16:45	When the whole body is affected: comorbidity and COPD	Symposium	BASIC
14:45-16:45	Maurizio Vignola Award for Innovation in Pneumology Ceremony (supported by Chiesi Foundation) followed by Clinical Year in Review I	Year in Review	CLINICAL
14:45-16:45	Improving adherence to maintenance medication in asthma: new tools for the clinician	Symposium	EPIDEMIOLOGY/ ENVIRONMENT
14:45-16:45	Nanosafety: human health risk assessment	Symposium	INFECTION
14:45-16:45	Joint session with WOA - The bacterial microbiota: implications for health and disease	Hot Topic	INTENSIVE CARE
17:15-19:15	New strategies, meaningful outcomes, and therapeutic options for COPD; <i>Organised by Novartis Pharma AG</i>	Evening Symposium	ONCOLOGY
17:15-19:15	Anticholinergics in Asthma: Could They Impact Exacerbations?; <i>Organised by Boehringer Ingelheim</i>	Evening Symposium	PAEDIATRIC
17:15-19:15	Seeing COPD from the patient's perspective; <i>Organised by Almirall S.A.</i>	Evening Symposium	PHYSIOLOGY
17:15-19:15	Continuity of care in asthma and COPD: Do we understand the future risks?; <i>Organised by AstraZeneca</i>	Evening Symposium	SLEEP
17:15-19:15	Idiopathic pulmonary fibrosis – challenges and perspectives in a rare disease; <i>Organised by Boehringer Ingelheim</i>	Evening Symposium	
17:15-19:15	Small airways: clinical implications; <i>Organised by Takeda Pharmaceuticals International</i>	Evening Symposium	

17:15-19:15	Changing the pneumococcal vaccination paradigm; <i>Organised by Pfizer International Operations</i>	Evening Symposium
17:30-19:00	Exhaled Nitric Oxide in Clinical Practice; <i>Organised by Aerocrine AB</i>	Evening Mini Symposium

TUESDAY 4 SEPTEMBER

08:30-10:30	Respiratory infectious diseases Grand Round - an interactive session	Grand Round
08:30-10:30	Paediatric Year in Review	Year in Review
08:30-10:30	Genetics and genomics in asthma and COPD: prediction and personalised medicine	Symposium
08:30-10:30	ERS Award for Rare Pulmonary Disease Ceremony (supported by GlaxoSmithKline) followed by symposium "Update on orphan lung diseases"	Symposium
08:30-10:30	Non-antibiotic effects of macrolides in lung disease	Symposium
08:30-10:30	Gender-related differences in pulmonary disease	Symposium
10:45-12:45	Research Award on Idiopathic Pulmonary Fibrosis Ceremony (supported by InterMune) followed by Clinical Grand Round - an interactive session	Grand Round
10:45-12:45	The promise of new drugs for treating asthma and COPD	Symposium
10:45-12:45	Modelling respiratory infections: is it the future or the present?	Symposium
10:45-12:45	COPD in non-smokers: an important neglected disease	Symposium
14:45-16:45	Ceremony for Pulmonary Arterial Hypertension Award (supported by Actelion) followed by Clinical Year in Review II	Year in Review
14:45-16:45	Good quality clinical recommendations for thoracic malignancy management in Europe	Symposium
14:45-16:45	Impact of traffic-related pollution on children's lungs	Symposium
14:45-16:45	ERS Romain Pauwels Research Award Ceremony (supported by GlaxoSmithKline) followed by the Hot Topic "The nerves are back!"	Hot Topic
17:15-19:15	Small airways involvement in respiratory diseases: a paradigm shift in diagnosis and management; <i>Organised by Chiesi Farmaceutici Spa</i>	Evening Symposium
17:15-19:15	From early diagnosis to long-term management of PAH patients; <i>Organised by GlaxoSmithKline</i>	Evening Symposium
17:30-19:00	It's Just a Matter of Time: a Case-Based Forum for Physicians Managing PAH; <i>Organised by United Therapeutics</i>	Evening Expert Forum

WEDNESDAY 5 SEPTEMBER

08:30-10:30	The updated ATS/ERS statement on pulmonary rehabilitation - update from the ATS/ERS Task Force	Hot Topic
08:30-10:30	New ATS/ERS recommendations for bronchoprovocation challenge testing	Symposium
08:30-10:30	Update on bronchiectasis	Symposium
08:30-10:30	ERS COPD Research Award Ceremony (supported by Boehringer Ingelheim) followed by the Hot Topic "It takes two to tango: innate and adaptive immunity in COPD"	Hot Topic
08:30-10:30	Infection control of respiratory pathogens	Symposium
10:45-12:45	Exercise testing in PAH patients	Symposium
10:45-12:45	New guidelines in respiratory infections	Symposium
10:45-12:45	Diagnosis and management of thymic malignancies: an update	Symposium
10:45-12:45	Contributing factors to pulmonary hypertension	Symposium
10:45-12:45	Unusual NIV applications for acute respiratory failure	Symposium

FREE COMMUNICATION SESSIONS

Abstracts

A total of 5,185 abstracts have been submitted. Accepted abstracts will be presented in Oral Presentations, Thematic Poster and Poster Discussion sessions. All selected abstracts will be available online from 26 August 2012 (00:08 am CET). For more information go to: www.erscongress2012.org

Note: Authors of accepted abstracts are responsible for spelling and syntax.

Oral Presentations

The presentation of abstracts accepted for Oral Presentation sessions will take place from Sunday to Wednesday during the Scientific Programme. Oral presentations comprise of up to eight 10-minute presentations, each followed by 5 minutes of discussion.

Thematic Posters

Posters accepted for Thematic Poster sessions will be displayed from Sunday to Tuesday for one day each in Hall A. Posters should be set up between 08:30 and 09:30 and removed by



17:00. Posters not removed by the author at the end of the day will be removed by staff and may be thrown away. Poster boards will be in **horizontal format 1.95 m wide x 1 m high**. Help desks in the Thematic Poster area will provide display materials and information.

Poster Discussion sessions

All abstracts accepted for Poster Discussion sessions will be presented in a paper format. Authors are required to prepare their poster online and print it in advance of the Congress. Posters will be displayed on the walls around the room and manned by the authors for the first hour; their format will be in **horizontal format 1.95 m wide x 1 m high**. During the second hour, the chairs will lead a general discussion of specific issues related to the session. These sessions will run from Sunday, 2 September to the morning of Wednesday, 5 September. Authors should arrive at the venue 15 minutes before the session is due to begin to ensure their poster is correctly displayed in the allocated place.

E-Poster Area

Sponsored by Almirall S.A.



All authors of an accepted abstract will be encouraged to create an electronic version of their work before the Congress in addition to their assigned type of presentation (e.g. Poster Discussion, Thematic Poster or Oral Presentation). Located in Hall C, the E-Poster area will allow delegates to access E-Posters on workstations throughout the duration of the Congress. Delegates, authors and chairs will be able to communicate and post comments on the data presented via a chat forum during and after the Congress.

Further information: *The electronic platform available at the Congress is a medium for presenting work during a live event. As with Thematic Posters, data published electronically is not considered a publication or a pre-publication. It is not available for review and may not be quoted, copied or downloaded. With the author's agreement, it will be made available online after the Congress. Copyright remains with the author.*



ERS/NEJM joint session



The ERS and the NEJM encourage physicians and scientists to submit original research articles by 1 April 2012 to be presented at the NEJM special lunchtime symposium. Submit your article via <https://cdf.nejm.org/misc/authors/> by 1 April 2012. Create a ScholarOne account, select "Eur Resp Soc Symp" as the article type, and indicate in the cover letter that the article is being submitted for consideration for publication in the Journal and for possible presentation at the NEJM special symposium at the ERS Annual Congress.

Late Breaking Abstract

Newsworthy and cutting-edge information?

Submit your Late Breaking Abstract from 1–31 May 2012. Only the best Late Breaking Abstracts will be accepted.

Submission fee: €75.

For more information go to: www.erscongress2012.org

Abstract Book

All accepted and presented abstracts can be referenced as a supplement of the *European Respiratory Journal*.

ERS Congress Abstracts on USB keys

Sponsored by Almirall S.A



With the support of Almirall S.A., the ERS is offering delegates an electronic copy of the ERS Congress Abstracts on USB keys, which they can collect free of charge from the Almirall S.A. exhibition stand in exchange for a voucher in their Congress bag. The USB keys will be distributed on a "first come, first served" basis.

Abstract Print Zone

Sponsored by Chiesi Farmaceutici SpA



The Abstract Print Zone gives delegates free access to PCs in designated areas. Here, delegates can select and print abstracts in exactly the same format as the official Abstract Book on USB key. Each PC will be equipped with its own printer with staff on hand to assist. Abstracts can be easily accessed through advanced search tools with three search options:

- by day and session
- by Scientific Assembly or Group
- by topic

All abstracts will be available for download and/or printing from 26 August 2012. For more information go to: www.erscongress2012.org

SPECIAL 2-DAY PACKAGE FOR ALLIED HEALTHCARE PROFESSIONALS*

Rates for special 2-day package (Saturday 1 September and Sunday 2 September 2012 only)

Early bird (until 15 June 2012)	Standard (from 16 June 2012)	On site
€265	€380	€430

All prices, categories and dates are indicative and subject to change.

The special 2-day package includes:

- Registration for 1 September and 2 September
- on 1 September: entrance to the morning Primary Care programme and one afternoon Postgraduate Course (PG) OR PG20 European Spirometry Driving Licence train-the-trainer (full day)
- on 2 September: access to all scientific sessions and Free Communication sessions

* i.e. nurses, physiotherapists and technologists. Prices and dates subject to change.

*Find out about cutting-edge techniques in respiratory medicine.
Register for the Allied Health Professionals 2-day package now!*

PROGRAMME SUGGESTED TRACK

Saturday, 1 September

09:30 - 13:00

Primary Care Programme

14:00 - 17:30

- PG11 Pulmonary fibrosis
- PG12 Cough: from basic mechanisms to clinical approaches
- PG13 AirPROM: patient specific modelling and systems biology living labs workshop
- PG14 From phenotypes to endotypes of asthma and COPD
- PG15 Common respiratory infections in childhood: current guidelines and controversies
- PG16 ERS/ACCP joint course on diagnostic and management strategies for pleural disorders
- PG17 Clinical failure of treatment of respiratory infections
- PG18 Recent evolutions in screening and early diagnosis of lung cancer
- PG19 Imaging in the intensive care unit

or

09:30 - 18:15

PG20 European Spirometry Driving Licence train-the-trainer

From 17:45

Opening ceremony

Sunday, 2 September

Access to all Symposia and Free Communication sessions (Oral Presentations, Poster Discussion and Thematic Poster sessions).

Please refer to the online programme for more details: [LINK](#).

8:30-10:30

An Olympic challenge: winners and losers in exercise training

10:45-12:45

Brian Whipp Memorial Symposium "Cardio-pulmonary exercise physiology: from olympic gold to clinical goals"

14:45-16:45

New tools to assess improvement in respiratory patients: capturing the patient's perspective

17:15 - 19:15

Evening Symposia

All prices, categories and dates are indicative and subject to change.

Find out about cutting-edge techniques in respiratory medicine.

Register for the Allied Health Professionals 2-day package now!

BE PART OF THE ERS FUTURE

FELLOWS' GET-TOGETHER

If you are interested in the ERS Fellowship Programmes, you are invited to join the “ERS Fellows’ Get-Together” on [Saturday, 1 September, from 13:00 to 16:30](#) which will provide invaluable information on funding opportunities and allow networking between young scientists. Moreover, this event will enable Fellows to present the results of their work. If you are a prospective Fellow you are encouraged to join the get-together and check for scientific outcomes which you could achieve on your own by applying for an ERS Fellowship.

Aims of the session:

- bring together ERS Fellows
- bring together experts involved in the reviewing procedure of the applications
- communicate their experience to anyone interested in applying for an ERS Fellowship
- provide a valuable networking platform for young individuals
- “How to build a career” presentation.

Young Scientist’s Networking Evening

The ERS Young Scientist’s Networking Evening will take place on Tuesday, [4 September from 17:30](#). Do not miss the opportunity to meet and interact with the leaders of the respiratory medicine and ERS leadership. The results of the ERS Best Poster Competition 2012 will be announced.



JOIN ERS *today!*

ERS brings together leading experts in respiratory medicine. As an ERS member you join a unique entity, European in origin with a world outlook, merging scientific enquiry with the desire to share and exchange knowledge and a commitment to the concept of lifelong learning. ERS membership identifies you as adhering to high professional standards in the field of respiratory medicine.

Each new member elects to join three of the ERS's 11 Scientific Assemblies (see below) through which you can contribute to the latest thinking on patient care, keep up-to-date with current progress in clinical practice and research and help determine the Scientific Programme of the world's most broad-based gathering of respiratory experts, the ERS Annual Congress.

A major benefit of ERS membership is access to the Society's diverse range of publications. All ERS members have electronic access to the *European Respiratory Journal (ERJ)*, the *European Respiratory Review (ERR)* and the *European Respiratory Monograph (ERM)* using their membership login details either directly through <http://ersjournals.com> or via the ERS website.

Some membership packages also include eligibility to receive printed issues of the *ERJ* and *ERM*. We do occasionally receive feedback that members no longer require print, for a number of reasons including a preference to read online or to be more environmentally aware. If this is the case, please let us know. In addition, eligible members will be contacted on an issue-by-issue basis for the *ERM* to opt to receive a printed copy, as we appreciate that not all topics are relevant for all.

Breathe, the respiratory professional's source for continuing medical education, is freely available electronically for members and non-members alike at www.breathejournal.org.

Anyone wishing to receive a free 3-year print subscription will need to opt in (subject to meeting the readership target criteria).

VISIT US AT THE ERS STAND TO FIND OUT MORE ABOUT THE RANGE OF MEMBERSHIP BENEFITS AVAILABLE!

- EXCHANGE KNOWLEDGE**
- FOSTER EDUCATION**
- PROMOTING RESEARCH**
- IMPROVING PATIENT CARE**

MEMBERSHIP CATEGORIES AND PRICES

GOLD		SILVER			
<input type="radio"/> 1 year € 170 <input type="radio"/> 3 years € 480	Dual** <input type="radio"/> 1 year € 145 <input type="radio"/> 3 years € 410	Scientist * (PhD, non-MD)	Allied Health Professional * (e.g. nurse, physiotherapist)	Under 35	Low Income Country GNP < USD 3000
Opt in for print issues of the ERJ <input type="radio"/> Yes <input type="radio"/> No Opt in for print issues of the ERM*** <input type="radio"/> Yes <input type="radio"/> No If yes POSTAL CHARGES: RESIDENTS OUTSIDE THE EU and opting for print copies of publications: <input type="radio"/> 1 year <input type="radio"/> 3 years (€ 25 per year)		<input type="radio"/> 1 year € 85 <input type="radio"/> 3 years € 240	<input type="radio"/> 1 year € 85 <input type="radio"/> 3 years € 240	<input type="radio"/> FREE OF CHARGE	<input type="radio"/> 1 year € 85 <input type="radio"/> 3 years € 240

Note: The 'Under 35' category is renewable annually.

*Proof of eligibility required

** Price reduction for members of: (please cross the box)

***You will be contacted on an issue-by-issue basis for each Edition of the ERM

- ATS APSR CTS EAACI
 ESCMID ESTS ISAM

PLEASE VISIT WWW.ERSNET.ORG/MEMBERSHIP FOR FURTHER DETAILS REGARDING MEMBERSHIP CATEGORIES, FEES AND ENTITLEMENTS

| EDUCATIONAL PROGRAMME

ERS AND EDUCATION

Postgraduate courses

The ERS Postgraduate courses provide medical practitioners with an opportunity to align their current procedures with the latest clinical best practice. These courses are linked to specific modules of the Harmonised Education in Respiratory Medicine for European Specialists (HERMES) syllabus; the schedule is designed to allow participants to attend up to two courses. Course materials are distributed onsite in the form of a course booklet. Registration for these courses is additional to the Congress registration fee and is €90 for early bird registrations and €120 for all other registrations.

Note: The HERMES syllabus summarises the body of knowledge of an adult, critical care, paediatric or sleep respiratory medicine specialist; it can help in benchmarking and determining the specialist's continuous medical education needs. HERMES syllabus items are identified as such in the programme of Postgraduate courses outlined in the following pages.

New in 2012 is the full-day HERMES spirometry train-the-trainer course. This course will provide those wishing to deliver the ERS European spirometry training programme with the skills, knowledge and qualification to train and certify participants for the European Spirometry Driving Licence. For more information please visit hermes.ersnet.org. Registration for this course is additional to the Congress registration fee and is €150 for early bird registrations and €180 for all other registrations.

Meet the Professor seminars

At these seminars an expert is on hand to stimulate discussion, answer questions and offer advice. The seminar format encourages a more personal approach to learning. Each of the 13 lunchtime seminars are limited to 40 participants, so book early to avoid disappointment. Registration for these courses is additional to the Congress registration fee and is €65 for early bird registration and €85 for all other registrations (a lunch box is included).

Morning Seminars

Morning Seminars are designed to provide participants with dynamic presentations and discussions while allowing the participants the opportunity to gain knowledge in the selected topics. They take place, as the name implies, in the morning, before the more "traditional" Congress content begins. This year, there are six morning seminars. Registration for these courses is additional to the Congress registration fee and is €65 for early bird registration and €85 for all other registrations.

Educational skills workshops

NEW 2012 - The educational skills workshops are designed to allow participants to gain practical skills in a discipline. The workshops will revolve around workstations, consequently traditional presentations and lectures will not be used. Participants will receive educational material. The maximum number of participants will be restricted to 40 per workshop. Registration for these workshops is additional to the Congress registration fee and is €65 for early bird registration and €85 for all other registrations.

HERMES European Examinations in adult respiratory medicine and paediatric respiratory medicine

The European examinations in adult and paediatric respiratory medicine are knowledge-based examinations and are composed of 90 multiple choice questions. In order to be eligible for the certification of the HERMES diploma, candidates must fulfil the requirements and meet specific registration procedures which can be found on hermes.ersnet.org.

The examinations in adult respiratory medicine and paediatric respiratory medicine are also open to candidates who would like to sit the examination as part of a self-assessment exercise or as an in-training assessment. Participation in the examination on this basis will not lead to the European diploma and it is not possible to convert to the European diploma after the examination.

Following completion of the examinations detailed individual feedback according to syllabus topics will be provided to allow participants to progress, those eligible may be awarded the European diploma.

	Adult respiratory medicine	Paediatric respiratory medicine
European diploma	€280	€350
In-training assessment	€140	€175
Self assessment	€140	€175

EDUCATIONAL PROGRAMME OVERVIEW

SATURDAY, 1 SEPTEMBER 2012

14:00-17:30 HERMES EXAMINATIONS

European examination in adult respiratory medicine
European examination in paediatric respiratory medicine

POSTGRADUATE COURSES

09:30-13:00 MORNING SESSION

- PG1 Interventional pulmonology procedures: best practice
- PG2 How to make NIV successful
- PG3 Radiological-pathological correlation of tumoural and non-tumoural pathology: an interdisciplinary approach
- PG4 Experimental models for respiratory medicine: strengths and limitations
- PG5 Obstructive sleep apnoea syndrome
- PG6 Hot topics in paediatric allergy
- PG7 TB and MDR-/XDR-TB: what is new in diagnosis, treatment and follow-up
- PG8 State-of-the-art management of sarcoidosis
- PG9 Progress on the treatment of COPD
- PG10 An update on mesothelioma diagnostics and treatment

14:00-17:30 AFTERNOON SESSION

- PG11 Pulmonary fibrosis
- PG12 Cough: from basic mechanisms to clinical approaches
- PG13 AirPROM: patient specific modelling and systems biology living labs workshop
- PG14 From phenotypes to endotypes of asthma and COPD
- PG15 Common respiratory infections in childhood: current guidelines and controversies
- PG16 ERS/ACCP joint course on diagnostic and management strategies for pleural disorders
- PG17 Clinical failure of treatment of respiratory infections
- PG18 Recent evolutions in screening and early diagnosis of lung cancer
- PG19 Imaging in the intensive care unit
- PG20 European spirometry train-the-trainer programme

SUNDAY, 2 SEPTEMBER 2012

13:00-14:00

MEET THE PROFESSOR

- MP1 Bronchoscopic treatment of emphysema
- MP2 Functional respiratory imaging
- MP3 Long-term non-invasive respiratory support in infants and children
- MP4 Challenges in the management of patients with nursing home-acquired pneumonia

- MP5 Particulate air pollution and COPD as risk factors for cardiovascular disease

EDUCATIONAL SKILLS WORKSHOPS

10:00-12:00

- WS1 Endoscopic lung volume reduction and endosonography

15:00-17:00

- WS2 Endoscopic lung volume reduction and endosonography

MONDAY, 3 SEPTEMBER 2012

07:00-08:15

MORNING SEMINAR

- MS1 Interpretation of sleep studies: problem areas
- MS2 Chronic pulmonary aspergillosis
- MS3 Update in idiopathic pulmonary fibrosis

EDUCATIONAL SKILLS WORKSHOPS

10:00-12:00

- WS3 Thoracic ultrasound

15:00-17:00

- WS4 Thoracic ultrasound

13:00-14:00

MEET THE PROFESSOR

- MP6 Medical treatment of ICU-acquired pneumonia
- MP7 Adaptive immunity in COPD
- MP8 Candidate selection for lung transplantation
- MP9 Standards in pleural fluid analysis and thoracoscopy

TUESDAY, 4 SEPTEMBER 2012

07:00-08:15

MORNING SEMINAR

- MS4 Interpreting high-resolution computed tomography scans: top tips
- MS5 Making sense of NIV in acute patients
- MS6 Severe asthma – diagnosis and treatment

13:00-14:00

MEET THE PROFESSOR

- MP10 Genomics of lung cancer
- MP11 What have we learned from the GA2LEN project?
- MP12 Assessing physical activity: where are we going?
- MP13 Systematic approach to interpreting chest images

HERMES EXAMINATIONS

14:00 - 17:00


 European examination in adult respiratory medicine


 European examination in paediatric respiratory medicine

POSTGRADUATE COURSES

MORNING SESSION

09:30 - 13:00

PG1 Interventional pulmonology procedures: best practice

Aims: To illustrate and discuss the technical aspects of some of the most common interventional pulmonology procedures including: EBUS-TBNA and EUS-FNA, airway stenting, endobronchial valves for emphysema treatment, and medical thoracoscopy. At the end of this course participants will know, in detail, the best way to perform the procedures.

HERMES module link: ADULT - D.2 Other procedures

Target audience: Respiratory physicians, pulmonologists, thoracic surgeons and trainees.

Chairs: S. Gasparini (Ancona, Italy), F. Herth (Heidelberg, Germany)

09:30 EBUS-TBNA and EUS-FNA: how do I do it?

C. Dooms (Leuven, Belgium)

10:15 Airway stenting: how do I do it?

H. Dutau (Marseille, France)

11:00 Break

11:30 Endobronchial valves for emphysema treatment: how do I do it and in which patients?

R. Eberhardt (Heidelberg, Germany)

12:15 Medical thoracoscopy: how do I do it?

G. Tassi (Gussago, Italy)

PG2 How to make NIV successful

Aims: To describe and discuss the technical aspects of NIV to ensure that the procedure is successful.

Topics covered include: selecting the right patient in the proper setting, choosing the correct interface, choosing and setting the correct ventilator, and identifying common mistakes that lead to failure.

HERMES module link: ADULT E.1 - Treatment modalities and prevention measures.

RESPIRATORY CRITICAL CARE Module 4 - Ventilation and airway management.

Target audience: Pulmonologists, emergency medicine doctors, respiratory therapists, respiratory physicians, intensivists and nurses.

Chairs: W. Windisch (Köln, Germany), S. Nava (Bologna, Italy)

09:30 The right patient in the proper setting

M. W. Elliott (Leeds, United Kingdom)

10:15 What interface for what patient?

P. Navalesi (Vercelli, Italy)

11:00 Break

11:30 Choice and setting of the ventilator

F. Di Marco (Milan, Italy)

12:15 Common mistakes leading to NIV failure

M. Ferrer (Barcelona, Spain)

PG3 Radiological-pathological correlation of tumoural and non-tumoural pathology: an interdisciplinary approach

Aims: To understand basic findings on imaging and pathology. To give an idea how imaging and pathology correlate in different pathologies, and how they can work together in finding solutions for clinical problems.

HERMES module links: ADULT - A.1 Structure and function of the respiratory system, B.2 Thoracic tumours.

Target audience: Pulmonologists, basic scientists, pathologists, radiologists, thoracic surgeons and trainees.

Chairs: W. De Wever (Leuven, Belgium)

09:30 Basic interpretation of computed tomography findings in the lung

W. De Wever (Leuven, Belgium)

10:15 Basic interpretation of histopathological findings in the lung

E. Brambilla (Grenoble, France)

- 11:00 Break
- 11:30 An interdisciplinary radiological–pathological approach of tumoural pathology
To be confirmed
- 12:15 An interdisciplinary radiological–pathological approach of non-tumoural pathology
W. De Wever (Leuven, Belgium)

PG4 Experimental models for respiratory medicine: strengths and limitations

Aims: This course will give an overview of important in vivo experimental models in rodents and newer evolutions that directly mimic COPD, acute lung injury, idiopathic pulmonary fibrosis and asthma, or specific pathophysiological aspects of these diseases. Also the strengths and limitations of the animal models if compared to human disease will be discussed.

The main learning objectives are:

1. To explain the strengths of the models by showing how they have given a new basis for the understanding of disease or a therapeutic approach.
2. To point out limitations in the models due to differences compared to the human diseases.
3. To consider the strengths and limitations of the models compared to clinical studies of patients with these diseases.

HERMES module links: ADULT A.1 Structure and function of the respiratory system, B.1 Airway diseases, B.3 Non-TB respiratory infections, B.7 Diffuse parenchymal (interstitial) lung diseases, F. Core generic abilities, I. Further areas relevant to respiratory medicine.

Target audience: Clinicians, clinical researchers, basic science researchers and students interested in the pathogenesis of COPD, asthma, acute lung injury and fibrosis, aiming to understand disease processes in vivo by experimental animal models, their relationship to in vitro experiments and human clinical data.

Chairs: K. Bracke (Laarne, Belgium), J. H. J. Vernooy (Maastricht, The Netherlands)

- 09:30 Cigarette smoke in mice, rats and guinea pigs: value to study pathogenesis of COPD
G. Brusselle (Ghent, Belgium)
- 10:15 Modelling acute lung injury: infections versus bacterial components
A. De Vos (Amsterdam, The Netherlands)
- 11:00 Break
- 11:30 Modelling pulmonary fibrosis
G. Laurent (London, United Kingdom)
- 12:15 Models of asthma in rodents: similarities and differences compared to patient asthma
S. Shore (Boston, United States of America)

PG5 Obstructive sleep apnoea syndrome

Aims: To provide a basic overview on obstructive sleep apnoea (OSA).

Topics covered will include: epidemiology and risk factors, pathophysiology of OSA, polysomnography and clinical assessment in children, and the consequences of OSA.

HERMES module links: SLEEP - 2 Respiratory conditions, 5 Diagnostic techniques, 8 Paediatric.

ADULT - B19 Sleep related disorders

PAEDIATRIC - Sleep medicine

Target audience: Pulmonologists, respiratory physicians, general practitioners and trainees.

Chairs: S. Andreas (Immenhausen, Germany), W. De Backer (Antwerp, Belgium)

- 09:30 Epidemiology and risk factors for OSA
D. Rodenstein (Brussels, Belgium)
- 10:15 Pathophysiology of OSA
M. Bonsignore (Palermo, Italy)
- 11:00 Break
- 11:30 Polysomnography and clinical assessment in children with OSA
S. Verhulst (Wilrijk, Belgium)
- 12:15 Consequences of OSA
P. Levy (Grenoble, France)

PG6 Hot topics in paediatric allergy

Aims: Asthma and allergy are the most prevalent chronic disorders in children in the western world, causing considerable morbidity.

This course aims to provide participants with state-of-the-art knowledge on different hot topics in paediatric allergy.

Topics covered include: immunotherapy in children, food allergies and anaphylaxis and the impact of rhinitis on asthma.

HERMES module links: PAEDIATRIC - Bronchial asthma and other wheezing disorders, Allergic disorders, Epidemiology and environmental health.

Target audience: Pulmonologists, respiratory physicians, paediatricians, allergologists, nurses and trainees.

Chairs: K. Lodrup Carlsen (Oslo, Norway), M. Pijnenburg (Rotterdam, The Netherlands)

- 09:30 Allergy in paediatric asthma: an overview
P.-L.-P. Brand (Zwolle, The Netherlands)
- 10:15 Immunotherapy in children with asthma
S. Halcken (Odense C, Denmark)
- 11:00 Break

- 11:30 Food allergies, anaphylaxis and asthma
G. Roberts (Southampton, United Kingdom)
- 12:15 Impact of allergic rhinitis on asthma
J. Bousquet (Montpellier, France)

PG7 TB and MDR-/XDR-TB: what is new in diagnosis, treatment and follow-up

Aims: This course is part of the TB-PAN-NET FP7 EU funded project. The aims of this course are to provide an overview of the state-of-the-art of MDR-/XDR-TB management in terms of new diagnosis techniques and treatment options.



HERMES module links: ADULT - A.1 Structure and function of the respiratory system, B.1 Airway diseases, B.4 Tuberculosis, C Symptoms and Signs, D.2 Other procedures, D.3 Procedures performed collaboratively, E Treatment modalities and prevention measures, F Core generic abilities, H. Knowledge of associated fields relevant to adult respiratory medicine, I. Further areas relevant to respiratory medicine.

Target audience: Pulmonologists, nurses, respiratory therapists, respiratory physicians, clinical researchers, thoracic surgeons, general practitioners, research fellows, trainees, public health doctors and public health nurses.

Chairs: D. Cirillo (Milan, Italy), G. Rohde (Maastricht, The Netherlands)

- 09:30 From traditional bacteriology to rapid molecular methods: the revolution is going on
K. Dheda (Cape Town, South Africa)
- 10:15 Exercise on how to include the new rapid methods into diagnostic algorithms
G. Sotgiu (Sassari, Italy)
- 11:00 Break
- 11:30 Evidence provided by recent meta-analyses on treatment: what is new?
G.-B. Migliori (Tradate, Italy)
- 12:15 MDR-/XDR-TB: what are the unresolved problems in the clinical management?
J.-P. Zellweger (Fribourg, Switzerland)

PG8 State-of-the-art management of sarcoidosis

Aims: To provide a state-of-the-art review of the management of sarcoidosis, including imaging, diagnosis, and therapy. To increase knowledge and skills on the use of EBUS and TBNA in the process of diagnosing sarcoidosis. To provide recent advances regarding cardiac involvement by sarcoidosis, a challenging and severe extrapulmonary involvement. To discuss evidence and experience in managing therapy, from oral corticosteroids to biologic targeted therapy, with experts.



HERMES module links: ADULT - B.5 Pulmonary vascular diseases, B.7 Diffuse parenchymal (interstitial) lung diseases.

Target audience: Pulmonologists, intensivists, emergency medicine doctors, nurses, respiratory therapists, pathologists, respiratory physicians, radiologists, clinical researchers, thoracic surgeons, general practitioners, allergologists, research fellows, otolaryngologists, basic scientists and trainees.

Chairs: V. Poletti (Forli, Italy), C. Robalo Cordeiro (Coimbra, Portugal)

- 09:30 Diagnosing sarcoidosis: recent advances and international guidelines
U. Costabel (Essen, Germany)
- 10:15 The challenge of cardiac sarcoidosis for the chest physician
C. Chapelon-Abrieu (Paris, France)
- 11:00 Break
- 11:30 Progress in imaging in pulmonary and extrapulmonary sarcoidosis
D. Lynch (Denver, United States of America)
- 12:15 Medical therapy of sarcoidosis: who to treat and how?
R. P. Baughman (Cincinnati, United States of America)

PG9 Progress on the treatment of COPD

Aims: To provide an update on new therapeutic modalities and recent advantages in COPD.



HERMES module links: ADULT - B.1 Airway diseases, B.10 Respiratory failure, E. Treatment modalities and prevention measures.

Target audience: Pulmonologists, respiratory therapists, respiratory physicians, research fellows and trainees.

Chairs: I. M. Adcock (London, United Kingdom), G. Caramori (Ferrara, Italy)

- 09:30 Improving COPD management through maximising bronchodilation
R. Buhl (Mainz, Germany)
- 10:15 Changes in the anti-inflammatory treatment of COPD
P. J. Barnes (London, United Kingdom)
- 11:00 Break
- 11:30 Treating systemic effects of COPD
M. Cazzola (Rome, Italy)
- 12:15 Nonmedical therapy for COPD
F.-J. Martinez (Ann Arbor, United States of America)

PG10 An update on mesothelioma diagnostics and treatment

Aims: In recent years, the surgical approach has shifted from pleuropneumonectomy to less extensive procedures, mostly to pleurectomy combined with chemo/radiation therapy. Preoperative nodal assessment is not uniform, although it is essential in preoperative selection. As pathology is particularly challenging, an update of current pathologic techniques and staging is always necessary. This course aims to give clear answers to the current controversies that are of practical benefit.

HERMES module links: ADULT - B.2 Thoracic tumours, H Knowledge of associated fields relevant to respiratory medicine.

Target audience: Pulmonologists, respiratory physicians, radiologists and thoracic surgeons.

Chairs: R.M. Huber (Munich, Germany), P. Van Schil (Antwerp, Belgium)

- 09:30 Contemporary diagnostics and staging
D. Waller (Leicester, United Kingdom)
- 10:15 Biomarkers in clinical decision making
A. Scherpereel (Lille, France)
- 11:00 Break
- 11:30 Role of chemotherapy and radiation therapy
K. Nackaerts (Leuven, Belgium)
- 12:15 Time trend and state-of-the-art of surgical treatment
To be confirmed

POSTGRADUATE COURSES**AFTERNOON SESSION**

14:00 - 17:30

PG11 Pulmonary fibrosis

Aims: This course will provide an overview on the current pathophysiology of lung fibrotic disorders and provide state-of-the-art information on possible therapeutic targets.

HERMES syllabus links: ADULT - B.7 Diffuse parenchymal

Target audience: Pulmonologists, research fellows, basic scientists and pathologists.

Chairs: K. Antoniou (Heraklion, Greece), B. Crestani (Paris, France)

- 14:00 ER and lysosomal stress as an underlying pathomechanistic principle in UIP
A. Guenther (Giessen, Germany)
- 14:45 Cellular plasticity in lung fibrosis: where are all fibroblasts coming from?
R. Strieter (Cambridge, United States of America)
- 15:30 Break
- 16:00 Secondary hits in the evolution of lung fibrosis: from smoke to viruses
J. J. G. Egan (Dublin, Ireland)
- 16:45 Coagulation in lung fibrosis: multiple pathways leading to fibroblast activation
K. Borensztajn (Amsterdam, The Netherlands)

PG12 Cough: from basic mechanisms to clinical approaches

Aims: This course will provide an understanding of the basic mechanisms, clinical presentation, diagnostic pathway and therapeutic options in treating patients with chronic cough.

HERMES modules links: ADULT - A.1 Structure and function of the respiratory system, B.1 Airway diseases.

Target audience: Pulmonologists, respiratory physicians, clinical researchers, research fellows, allergologists, trainees and basic scientists.

Chairs: A. Morice (Cottingham, United Kingdom), R. Sakalauskas (Kaunas, Lithuania)

- 14:00 Assessment of the patient with chronic cough
To be confirmed
- 14:45 The cough reflex: lessons from neurological disease
To be confirmed
- 15:30 Break
- 16:00 Physical therapy in the treatment of chronic cough
A. Vertigan (Newcastle, Australia)
- 16:45 Drug treatments and the cough reflex
P. Dicipinigaitis (Bronx, United States of America)

PG13 AirPROM: patient specific modelling and systems biology living labs workshop

Aims: This course will provide an overview of the concept of patient specific modelling and the potential for the use of patient specific models in personalised medicine. The course will demonstrate the use of patient specific models using example problems submitted by attendees, and teach the concepts of systems medicine.

HERMES module links: ADULT - D.3 Procedures performed collaboratively, F Core generic abilities.

Target audience: Pulmonologists, respiratory physicians, clinical researchers, general practitioners, research fellows, trainees, radiologists, thoracic surgeons and basic scientists.

Chairs: C. Brightling (Leicester, United Kingdom), I. Horvath (Budapest, Hungary)

- 14:00 The need and potential of patient specific modelling
C. Brightling (Leicester, United Kingdom)
- 14:45 Modelling the lung from two-dimensional to multi-scale approaches
K. Burrows (Oxford, United Kingdom)
- 15:30 Break
- 16:00 Systems biology: 21st century science
C. Auffray (Villejuif, France)
- 16:45 Living lab demonstration of attendee submitted clinical and research problems
S. Siddiqui (Leicester, United Kingdom)

PG14 From phenotypes to endotypes of asthma and COPD

Aims: This course will give an overview of the journey from phenotypes to endotypes of asthma and COPD. Asthma and COPD are not single disease entities. Both asthma and COPD, particularly COPD, include different clinical phenotypes with different risk factor patterns, clinical presentations and have large variations in prognosis. However, phenotypes do not express or explain the different underlying patho-physiological and pathogenetic mechanisms of the disease or phenotypes of disease. Thus, the term endotype has been introduced in order to explain both the clinical expressions of the disease phenotypes and their underlying mechanisms. Partly as a result of ongoing discussions on phenotypes and endotypes, there is also an ongoing debate about the need to revise the taxonomy of obstructive airway diseases.

HERMES module links: ADULT - B.1 Airway diseases, B.6 Occupational and environmental diseases.

Target audience: Pulmonologists, emergency medicine doctors, nurses, pathologists, respiratory physicians, radiologists, clinical researchers, general practitioners, allergologists, research fellows and basic scientists.

Chairs: G. Joos (Ghent, Belgium), B. Lundback (Gothenburg, Sweden)

- 14:00 From phenotypes to endotypes of asthma: why and how?
J. Lotvall (Gothenburg, Sweden)
- 14:45 Phenotypes and endotypes of severe asthma
S. Wenzel (Pittsburgh, United States of America)
- 15:30 Break
- 16:00 Clinically important results of phenotyping and endotyping of COPD: the ECLIPSE study
J. Vestbo (Hvidovre, Denmark)
- 16:45 Taxonomy proposal for up-dating the obstructive syndrome: where are we now?
R. Beasley (Wellington, New Zealand)

PG15 Common respiratory infections in childhood: current guidelines and controversies

Aims: To provide: an overview of the current guidelines and controversies for frequently occurring paediatric respiratory infections, such as viral bronchiolitis and community-acquired pneumonia (CAP); and insight into the changing epidemiology of CAP and pleuritis in childhood due to vaccination, controversies in the management of parapneumonic effusions and the diagnostic approach of recurrent pneumonia.

HERMES module links: PAEDIATRIC - Acute and chronic lung infection, Bronchial asthma and other wheezing disorders, Rare diseases, Epidemiology and environmental health.

Target audience: Pulmonologists, respiratory physicians, clinical researchers, general practitioners, paediatricians, radiologists and trainees.

Chairs: E. Eber (Graz, Austria), F. De Benedictis (Ancona, Italy)

- 14:00 Community-acquired pneumonia in children
J. Hull (Oxford, United Kingdom)
- 14:45 Acute viral bronchiolitis
C. Wainwright (Brisbane, Australia)
- 15:30 Break
- 16:00 Pleuritis and empyema
S. Ranganathan (Parkville, Australia)
- 16:45 Recurrent pneumonia in childhood
G. Piacentini (Verona, Italy)

PG16 ERS/ACCP joint course on diagnostic and management strategies for pleural disorders

Aims: This course will provide an understanding of and review common radiographic, CT and ultrasound findings in pleural disease. The aims of the course are to: review the diagnosis of empyema and understand non-surgical and surgical approaches to empyema management; provide understanding of the epidemiology, presentation and management options of spontaneous, traumatic and iatrogenic pneumothorax; and review diagnostic strategies and management options for malignant effusions, including pleurodesis and indwelling pleural catheters.



HERMES links: ADULT - B.11 Pleural diseases.

Chairs: V. Cottin (Lyon, France), M. Baumann (Jackson, United States of America)

- 14:00 Pleural imaging
F. Gleeson (Oxford, United Kingdom)
- 14:45 Pneumothorax
M. Baumann (Jackson, United States of America)
- 15:30 Break
- 16:00 Pleural infection and empyema
N. Maskell (Bristol, United Kingdom)
- 16:45 Malignant pleural disease
Y. Gary Lee (Crawley, Australia)

PG17 Clinical failure of treatment of respiratory infections

Aims: To describe the frequency and risk factors for treatment failure in lower respiratory tract infections. Provide insight into strategies directed to reduce the treatment failure in a variety of different respiratory infections in the adult.



HERMES module links: ADULT - B.1 Airway diseases, B.3 Non-TB respiratory infections.

Target audience: Pulmonologists, clinical researchers and general practitioners.

Chairs: G. Dimopoulos (Athens, Greece), G. Rohde (Maastricht, The Netherlands)

- 14:00 The role of increasing bacterial resistance
H. Goossens (Edegem, Belgium)
- 14:45 Treatment failure of community-acquired pneumonia: risk factors and consequences
A. Torres (Barcelona, Spain)
- 15:30 Break
- 16:00 Treatment failure of severe and ventilator-associated pneumonia
T. Welte (Hanover, Germany)
- 16:45 Treatment failure of infective exacerbations of COPD
A. Anzueto (San Antonio, United States of America)

PG18 Recent evolutions in screening and early diagnosis of lung cancer

Aims: This course will: demonstrate the role of integrating molecular techniques in future lung cancer screening programmes; show how exhaled breath analysis might contribute to the early, noninvasive diagnosis of lung cancer; describe the role of new endoscopy techniques in the screening and early diagnosis of lung cancer; and demonstrate the impact of screening with low-dose chest CT scan on lung cancer mortality in at risk populations.



HERMES module links: ADULT B.2 - Thoracic tumours, B.6 Occupational and environmental diseases, D.2 Other procedures, D.3 Procedures performed collaboratively, I. Further areas relevant to respiratory medicine.

Target audience: Pulmonologists, pathologists, respiratory physicians, radiologists, clinical researchers, thoracic surgeons and trainees.

Chairs: K. Nackaerts (Leuven, Belgium), H. De Koning (Rotterdam, The Netherlands)

- 14:00 Is CT-based screening for lung cancer finally ready for prime time?
H. De Koning (Rotterdam, The Netherlands)
- 14:45 The practical approach to incidental (sub)centimetric nodules
W. De Wever (Leuven, Belgium)
- 15:30 Break
- 16:00 The role of bronchoscopy in the screening and early diagnosis of lung cancer
L. Thiberville (Rouen, France)
- 16:45 Breath biomarkers for lung cancer detection: ready for use by the pulmonologist?
M. Corradi (Parma, Italy)

PG19 Imaging in the intensive care unit

Aims: This course aims to illustrate how combining 'old' and new techniques to approach the critical patient can lead to better outcomes.

Topics include bedside ultrasounds, choosing the right imaging technique, ultrasound and acute respiratory failure, and clinical case examples.



HERMES module links: ADULT - 2 Other procedures
RESPIRATORY CRITICAL CARE - Module 16: practical skills

Target audience: Pulmonologists, intensivists, emergency medicine doctors, respiratory therapists, respiratory physicians, radiologists and clinical researchers.

Chairs: P. Navalesi (Vercelli, Italy), S. Orfanos (Haidari, Greece)

- 14:00 What do ultrasounds at the bedside really tell me?
F. Corradi (Genoa, Italy)
- 14:45 Chest x-ray, CT scans, or HRCT for imaging of the critical lung: when and why?
To be confirmed
- 15:30 Break
- 16:00 Thoracic ultrasound for the patient with acute respiratory failure
D. Lichtenstein (Boulogne, France)
- 16:45 Clinical cases that I do not forget
To be confirmed

PG20 European spirometry train-the-trainer programme

Aims: To provide those wishing to deliver the ERS European spirometry training programme with the skills, knowledge and qualification to train and certify participants for the European Spirometry Driving Licence level I and level II within Europe.



HERMES syllabus links: ADULT - A1 Structure and function of the respiratory system, B1 Airway diseases, D1 Pulmonary function testing.

Target audience: The ERS spirometry train-the-trainer programme is aimed at those who would like to become directors or instructors of the European Spirometry Driving Licence training programme. As well as pulmonologists, respiratory therapists, respiratory physicians, general practitioners, nurses, lung function technologist/scientist.

Chairs: B.G. Cooper (Birmingham, United Kingdom), I. Steenbruggen (Zwolle, The Netherlands)

- 09:30 Overview of the European Spirometry Driving Licence training
B.G. Cooper (Birmingham, United Kingdom), I. Steenbruggen (Zwolle, The Netherlands)
- 10:00 Organising a European spirometry training programme
F. Burgos (Barcelona, Spain)
- 10:45 Break
- 11:00 Techniques of teaching and learning styles
J. Busari (Heerlen, The Netherlands)
- 12:30 European Spirometry Driving Licence specific teaching and training
J. Lloyd (Staffordshire, United Kingdom)
- 13:30 Lunch
- 14:15 Presentation and facilitation skills
O. Van Eck (Waalre, The Netherlands)
- 15:00 Assessment of the European Spirometry Driving Licence programme
J. Lloyd (Staffordshire, United Kingdom)
- 16:00 Discussion and feedback session
V. Habes (Utrecht, The Netherlands)

MEET THE PROFESSOR

13:00-14:00

MP1 Bronchoscopic treatment of emphysema

S. Gasparini (Ancona, Italy)

MP2 Functional respiratory imaging

A. Aliverti (Milan, Italy)

MP3 Long-term non-invasive respiratory support in infants and children

C. Roehr (Berlin, Germany)

MP4 Challenges in the management of patients with nursing home-acquired pneumonia

S. Ewig (Bochum, Germany)

MP5 Particulate air pollution and COPD as risk factors for cardiovascular disease

D. Gutterman (Milwaukee, United States of America)

EDUCATIONAL SKILLS WORKSHOPS

10:00 - 12:00

WS1 Endoscopic lung volume reduction and endosonography

15:00 - 17:00

WS2 Endoscopic lung volume reduction and endosonography

MORNING SEMINAR

07:00-08:15

MS1 Interpretation of sleep studies: problem areas

Aims: The aim of this session is to address some problem areas where additional techniques can be implemented to support differential diagnosis or treatment in sleep apnoea patients with cardiorespiratory comorbidity. Analysis of the breathing cycle in central apnoea will help to differentiate between idiopathic central apnoea and Cheyne-Stokes ventilation in patients with chronic heart failure, while the detection of concomitant hypoventilation in respiratory problems deserves more attention. Monitoring tools are not only indicated to explore breathing disturbances, but also to evaluate compliance and treatment success in the sleep laboratory and in the patient's home. An overview will be given of various monitoring tools, such as memory cards, in-built time counters and telemonitoring, and interpretation of recorded data.

Chair: M. Bonsignore (Palermo, Italy)

- 07:00 Introduction from the Chair
- 07:10 Diagnostic sleep studies in sleep apnoea with cardiorespiratory comorbidity
J. Verbraecken (Antwerp, Belgium)
- 07:35 Monitoring of treatment success
K.E. Bloch (Zurich, Switzerland)
- 08:00 Discussion

MS2 Chronic pulmonary aspergillosis

Chair: To be confirmed

- 07:00 Introduction from the Chair
- 07:10 Epidemiology, risk factors and clinical spectrum of chronic pulmonary aspergillosis
K. Mortensen (Copenhagen, Denmark)
- 07:35 Prevention: medical and surgical treatment of chronic pulmonary aspergillosis
G. Dimopoulos (Athens, Greece)
- 08:00 Discussion

07:00 - 08:15

MS3 Update in idiopathic pulmonary fibrosis

Chair: U. Costabel (Essen, Germany)

- 07:00 Introduction from the Chair
- 07:10 Idiopathic pulmonary fibrosis: an old disease revisited?
M. Kolb (Hamilton, Canada)
- 07:35 Advances in the therapeutical management of IPF
L. Richeldi (Modena, Italy)
- 08:00 Discussion

MEET THE PROFESSOR

13:00-14:00

MP6 Medical treatment of ICU-acquired pneumonia

A. Torres (Barcelona, Spain)

MP7 Adaptive immunity in COPD

M. Saetta (Padova, Italy)

MP8 Candidate selection for lung transplantation

M. Iversen (Copenhagen, Denmark)

MP9 Standards in pleural fluid analysis and thoracoscopy

J. Tschopp (Crans-Montana, Switzerland)

EDUCATIONAL SKILLS WORKSHOPS

10:00 - 12:00

WS3 Thoracic ultrasound

15:00 - 17:00

WS4 Thoracic ultrasound

MORNING SEMINAR

07:00-08:15

MS4 Interpreting high-resolution computed tomography scans: top tips

Chair: C. Vancheri (Catania, Italy)

07:00 Introduction from the Chair

07:10 HRCT in COPD

M. Pistolesi (Florence, Italy)

07:35 Interstitial lung diseases

S. Walsh (London, United Kingdom)

08:00 Discussion

MS5 Making sense of NIV in acute patients

Aims: To clarify important issues on NIV management for both hypoxaemic and hypercapnic acute patients

Chair: P. Pelosi (Genoa, Italy)

07:00 Introduction from the Chair

07:10 Just do it. NIV for acute hypercapnic patients: the “when and where”

M. W. Elliott (Leeds, United Kingdom)

07:35 Handle with care. NIV for acute hypoxaemic patients: the “who and how”

P. Navalesi (Vercelli, Italy)

08:00 Discussion

MS6 Severe asthma – diagnosis and treatment

Aims: To illustrate how to diagnose severe asthma in the clinic.

To demonstrate the advantages of using published definitions to define patient subsets.

To show how biomarker expression may determine therapy.

Chair: K.F. Chung (London, United Kingdom)

07:00 Introduction from the Chair

07:10 The BTS severe asthma cohort experience

A. Menzies-Gow (London, United Kingdom)

07:35 Biomarkers and personalised treatment

P. Chanez (Marseille, France)

08:00 Discussion

TUESDAY
4

MEET THE PROFESSOR

13:00-14:00

MP10 Genomics of lung cancer

P. Massion (Tennessee, United States of America)

MP11 What have we learned from the GA2LEN project?

P. Burney (London, United Kingdom)

MP12 Assessing physical activity: where are we going?

T. Troosters (Leuven, Belgium)

MP13 Systematic approach to interpreting chest images

S. Raouf (Brooklyn, United States of America)

| SCIENTIFIC PROGRAMME

09:30-13:00

SY Symposium: Primary Care Programme

Aims: This Primary Care Programme will provide the latest insights and evidence for diagnosing and managing respiratory diseases in a primary care setting.

Target audience: Clinicians, GPs, family physicians, pulmonary specialists, allied respiratory professionals and respiratory patient representatives.

- 09:30 Evidence basis and relevance of spirometric indices in diagnosis and follow-up of respiratory diseases in primary care
- 10:00 The impact of respiratory diseases on a working population.
- 10:30 Point of care testing and antibiotic prescribing for lower respiratory tract infections: what does the GP need to know?
- 11:00 Break
- 11:30 What comorbidities do have a clinically relevant impact on mortality in primary care respiratory diseases patients, and how to cope with them?
- 12:00 Oxygen@home: benefits, practical implications and pitfalls
- 12:30 Improving the differential diagnosis of respiratory diseases in primary care

08:30 - 08:50

Award for Achievement in the field of NSCLC Ceremony (supported by AstraZeneca)

08:50 - 10:30

followed by Grand Round on "How to diagnose and manage NSCLC with the new drugs - an interactive session"

Aims: The therapeutic management of advanced NSCLC underwent a therapeutic revolution in recent years. The use of TKI specific to addictive molecular abnormalities (EGFR mutations, ALK translocation) in patients whose tumours carried such mutations has been associated with major and prolonged objective response. The best use of platinum-based doublets and especially the development of maintenance strategies also provide therapeutic benefit in overall survival. It is important that pulmonologists and oncology-pneumologists can integrate this data into their clinical practice. The aim of this session will be to illustrate by exemplary clinical cases the diagnostic approach of addictive mutations, the practical use of TKI, what to do in case of toxicities and progression, and finally to address the concepts of the continuation maintenance or switch maintenance.

Target audience: Chest physicians, thoracic surgeons and oncologists.

- 08:50 To continue or not to continue, that is the question?
- 09:15 A woman with addiction
- 09:40 A man who was sick because of signet rings
- 10:05 Ressuscitate then let die

08:30 - 10:30

Symposium: Pulmonary injury and repair from alveolus to vessel walls

Aims: With this symposium, the audience will get a unique chance to learn about mechanisms of injury and repair in different compartments of the pulmonary system, delivered by renowned international experts. The presentations will highlight the similarities and differences between the pathomechanisms and how the disease course might be affected by novel growth factor-targeted and cell-based therapies.

Target audience: Respiratory clinicians (both adult and paediatric), clinical researchers, basic scientists and Postdoctoral fellows.

Chairs: V. Cottin (Lyon, France), M. Kolb (Hamilton, Canada)

- 08:30 Vascular density in fibrotic ILD: too much or not enough vessels?
M. Keane (Dublin, Ireland)
- 09:00 Smoking, emphysema and the vasculature
N. Voelkel (Richmond, United States of America)
- 09:30 Is alveolar and vascular remodelling in the lung reversible? Novel growth factor-related therapies
G. Jenkins (Nottingham, United Kingdom)
- 10:00 Amniotic stem cells for repair of injured alveoli and vasculature
D. Warburton (Los Angeles, United States of America)

08:30 - 10:30

Symposium: Pro-Con Debate "Severe community-acquired pneumonia: a lung disease?"

Aims: At the end of this symposium, participants will know:

- how to use severity scores according to their limitations and pitfalls,
- how to identify patients at risk of complication, assessing and treating acute respiratory failure and sepsis.

Target audience: Pneumologists, intensivists, emergency physicians, internists and fellows in respiratory diseases, intensive care and internal medicine.

Chairs: R. Cosentini (Milan, Italy), M. Ferrer (Barcelona, Spain)

- 08:30 PRO: Severity scores are useful
M. Woodhead (Manchester, United Kingdom)
- 09:00 CON: Severity scores are not useful
J. Chalmers (Edinburgh, United Kingdom)
- 09:30 Outcome of severe pneumonia: respiratory failure matters
A. Torres (Barcelona, Spain)
- 10:00 Outcome of severe pneumonia: sepsis matters
S. Ewig (Bochum, Germany)

08:30 - 10:30

Symposium: An Olympic challenge: winners and losers in exercise training**Aims:** The aims of this symposium are to:

- describe the currently available boundaries of exercise training in patients with chronic respiratory disease,
- describe the characteristics of the newly available modalities of exercise training which have been recently studied and applied,
- describe the available evidence on these modalities
- provide a critical view on whether these modalities are already currently applicable in the clinical practice.

Target audience: Clinicians, physicians, physiologists, physiotherapists and other allied health professionals.**Chairs:** F. Maltais (Quebec, Canada), T. Troosters (Leuven, Belgium)

- 08:30 Current boundaries of exercise training in chronic respiratory disease
E. Clini (Modena, Italy)
- 09:00 Going tougher on the muscle: the physiology behind one-legged exercise training
T. Dolmage (Toronto, Canada)
- 09:30 New trends and hypes in exercise training: what is the evidence?
M. A. Spruit (Horn, The Netherlands)
- 10:00 Exercise in the ICU
R. Gosselink (Leuven, Belgium)

08:30 - 10:30

Symposium: Asthma from childhood to adulthood: what factors predict the outcome?**Aims:** The audience will become updated and learn about:

- the incidence, remission and relapse of asthma from childhood to adulthood;
- the importance of different clinical phenotypes in these aspects;
- what the important determinants are for becoming free from asthma;
- what important knowledge birth cohort studies have contributed to clinical work and science.

Target audience: Lung/respiratory and paediatric clinicians, GPs and community medicine workers, epidemiologists, occupational physicians and allied health personnel, nurses, health educators and researchers.**Chairs:** E. Eber (Graz, Austria), B. Lundback (Gothenburg, Sweden)

- 08:30 Asthma from childhood to adulthood: the scenario of incidence, remission and relapse
M. Sears (Hamilton, Canada)
- 09:00 The impact of different asthma phenotypes on the outcome
E. von Mutius (Munich, Germany)
- 09:30 Factors related to temporary and lasting remission of asthma
E. Ronmark (Lulea, Sweden)
- 10:00 What have we learned from birth cohort studies?
F. Martinez (Tucson, United States of America)

08:30 - 10:30

Hot Topic: Respiratory support in children and young adults with neuromuscular disease**Aims:** To review the evidence for treatment options and listen to discussion of the latest practice from a range of experts in the area.**Target audience:** Although most patients with progressive neuromuscular disease are below 16 years of age, an increasing number of young adults are being transferred to adult care, much as happened with cystic fibrosis over the last decade. Paediatricians, adult respiratory clinicians, intensivists, physiotherapists and lung function staff are all likely to see increasing numbers of these patients in their practice.

- 08:30 Respiratory assessment of the neuromuscular patient
- 09:00 Airway clearance techniques in children with neuromuscular disease: when, how and what technique?
- 09:30 Non-invasive ventilation in children with neuromuscular disease: when, how and for how long?
- 10:00 Duchenne in the older patient: the Danish experience

08:30 - 10:30

Symposium: New advances in ICU-acquired weakness

Aims: This symposium will provide an update on new research surrounding the syndrome of ICU acquired weakness from a basic science and clinical perspective. It will discuss new evidence for preventive and therapeutic treatment strategies.

Target audience: Pulmonologists, intensivists, clinicians, nurses and physiotherapists.

Chairs: A. Artigas (Sabadell, Spain), P. Pelosi (Genoa, Italy)

- 08:30 ICU-acquired weakness: what are the mechanisms?
N. Hart (London, United Kingdom)
- 09:00 ICU-acquired weakness: an overview of the problem
T. Vassilakopoulos (Athens, Greece)
- 09:30 ICU-mobilisation to facilitate patient discharge
J. Hall (Chicago, United States of America)
- 10:00 Long-term outcomes in patients with ICU-acquired weakness
E. Wilcox (Toronto, Canada)

10:45 - 12:45

Cournand Lecture followed by Hot Topic: "Early intervention in CF: why, when and how?"

10:45 - 12:45

Symposium: Current challenges in multimodality lung cancer treatment

Aims: The audience will get updated information about the individualised approach related to risk assessment depending on the anticipated surgery, optimal multimodality lung cancer treatment, and some specific situations such as Pancoast tumours requiring a specific approach. Updated information about therapeutic approach in early and very advanced lung cancer will be provided.

Target audience: Pulmonary physicians, thoracic oncologists and thoracic surgeons.

Chairs: R.-M. Huber (Munich, Germany), D. Subotic (Belgrade, Republic of Serbia)

- 10:45 Which type of preoperative risk assessment for which patients
A. Brunelli (Ancona, Italy)
- 11:15 Pitfalls of neoadjuvant treatment
P. Van Schil (Antwerp, Belgium)
- 11:45 Contemporary approach to Pancoast tumours
D. Grunenwald (Paris, France)
- 12:15 Current indications to extended resections and bronchovascular reconstructions
F. Venuta (Rome, Italy)

10:45 - 12:45

Hot Topic: Brian Whipp Memorial Symposium "Cardio-pulmonary exercise physiology: from olympic gold to clinical goals"

Aims: The aims of this sessions are to: - describe the conditions under which the respiratory system influences exercise performance in athletes; - critically review the evidence showing that female endurance athletes may be more susceptible to pulmonary system limitation during exercise; - present new applications of CPET. Delegates will (i) become aware of the potential for using CPET as an indicator for success of chemotherapy; (ii) be updated on the usefulness of CPET in assessing preoperative and perioperative risk in a wide variety of surgical procedures and (iii) understand the usefulness of standardised guidelines for CPET in perioperative assessment and other physiological stresses will be outlined.

Target audience: Exercise physiologists, respiratory physicians, technicians, clinicians, surgeons, respiratory function technologists/scientists, physiotherapists and oncologists.

- 10:45 Respiratory determinants of endurance performance in athletes
- 11:15 Revisiting dysanapsis: gender-based differences in the pulmonary response to endurance exercise
- 11:45 The effect of chemotherapy on physical fitness objectively measured using cardiopulmonary exercise testing (CPET)
- 12:15 Preoperative exercise training and outcome following surgery

10:45 - 12:45

Symposium: Cochrane reviews in airway diseases

Aims: The objective of this symposium is to provide an understanding of the latest evidence available to clinicians and guideline writers to inform their clinical decisions and recommendations for practice. We will discuss the latest pharmacotherapies and biomarkers for asthma as well as pharmacotherapies and decision making pathways in COPD.

Target audience: Clinicians, guideline writers and anyone with an interest in using evidence in practice.

Chairs: C. Cates (Watford, United Kingdom), J. White (York, United Kingdom)

- 10:45 Cochrane reviews at the bedside: translational paths from clinical trials to medical decision making for COPD patients
M. Puhan (Zurich, Switzerland)
- 11:15 Evidence on influenza treatment and prevention
P. Doshi (Cambridge, United States of America)
- 11:45 The management of acute asthma in adults: the role of the Cochrane Airway Group (CAG) reviews
A. Magnan (Nantes, France)
- 12:15 What's new in childhood asthma: myths and realities
F. Ducharme (Montreal, Canada)

10:45 - 12:45

Symposium: Prevention and treatment of infective exacerbations of COPD

Aims: At the end of this symposium, the audience will have a better knowledge about the clues for identifying the bacterial and viral aetiology of exacerbations of COPD and, therefore, clear guidelines about the appropriate prescription of antibiotics will be provided.

Target audience: Clinicians, microbiologists and researchers in respiratory infections.

Chairs: A. Anzueto (San Antonio, United States of America), J. Wedzicha (London, United Kingdom)

- 10:45 How can we identify viral exacerbations of COPD?
G. Rohde (Maastricht, The Netherlands)
- 11:15 Beyond the Anthonisen criteria: how can we identify bacterial exacerbations of COPD?
M. Miravittles (Barcelona, Spain)
- 11:45 How can we better treat infective exacerbations of COPD?
G. Dimopoulos (Athens, Greece)
- 12:15 How can we better prevent exacerbations of COPD?
S. Sethi (Buffalo, United States of America)

10:45 - 12:45

Hot Topic: Searching for the secrets of senescence in the lung

Aims: At the end of the session, the audience will understand:

- molecular mechanism of ageing in organisms;
- how evidence about accelerated ageing in chronic lung diseases is provided;
- how to identify novel pathways for lung ageing;
- how to identify new potential targets for treatment of chronic lung disease.

Target audience: Clinical researchers, clinicians, pharmaceutical industry and basic scientists.

- 10:45 Molecular mechanisms of ageing
- 11:15 COPD as an age-related disease
- 11:45 Premature ageing in IPF
- 12:15 Ageing of the immune system: a contribution to lung disease?

10:45 - 12:45

Symposium: Paediatric lung function today

Aims: This symposium will update the audience about new and developing measurements of lung function in children. There is a wide variation in the delivery of lung function services to children across Europe, where some centres are purely paediatric for testing, many centres are adult testing services being asked to test children. This session will outline the state-of-the-art of paediatric lung function testing and highlight areas of difficult service provision. Two novel techniques will be explored to show the potential of new technology: FeNO and LCI.

Target audience: Paediatric nurses, respiratory function technologists, scientists, pulmonologists with an interest in lung function testing in children, and paediatric pulmonologists and paediatricians.

Chairs: S. Lone Latif (Amsterdam, The Netherlands), J. Makonga-Braaksma (Woudenberg, The Netherlands)

- 10:45 Lung function testing in children: are children small adults?
J. Stocks (London, United Kingdom)
- 11:15 Reference values for paediatric pulmonary function testing: glee about GLI
G. Hall (Perth, Australia)
- 11:45 Measuring FeNO in children
A. Olin (Gothenburg, Sweden)
- 12:15 Lung clearance index
P. Gustafsson (Skovde, Sweden)

14:45 - 16:45

Imaging Grand Round - an interactive session

Aims: Demonstration and discussion of characteristic imaging findings in patients with infectious disease with normal immune systems and neutropenia. Furthermore, inhalational lung diseases and rare lung diseases will be presented. This session will provide imaging strategies for different patient populations.

Target audience: Clinicians and all health professionals caring for patients with various lung diseases requiring imaging for non-invasive disease characterisation.

- 14:45 Community acquired infectious diseases
- 15:15 Infectious disease in immunocompromised patients
- 15:45 Inhalational lung diseases
- 16:15 Miscellaneous diffuse lung diseases

14:45 - 16:45

Symposium: Unimodal treatment for non-small cell lung cancer: dawn of a renaissance?

Aims: The audience will learn the modern indications of unimodal treatment for lung cancer, taking into account stage, histology, performance status, age and comorbidities.

Target audience: All those who are managing patients with lung cancer: chest physicians, medical oncologists, thoracic surgeons, radiation oncologists, nurses, etc.

Chairs: S. Elia (Rome, Italy), F. Gamarra (Munich, Germany)

- 14:45 Limited resection for stage I disease
G. Stamatis (Essen, Germany)
- 15:15 Results of modern radiotherapy alone from stage I to stage III
F. Lagerwaard (Amsterdam, The Netherlands)
- 15:45 A reasonable choice for cytostatic monotherapy in advanced disease
E. Quoix (Strasbourg, France)
- 16:15 Targeted substances and no more?
A.-P. Meert (Brussels, Belgium)

14:45 - 16:45

Symposium: COPD and OSA: two prevalent diseases related to cardiovascular disease by common mechanism?

Aims: Based on the background of the causes of cardiovascular disease in OSA and COPD, contemporary strategies for prevention and treatment of cardiovascular disease will be presented. The challenge on how to integrate this knowledge into the treatment of patients with COPD and OSA in clinical routine will be addressed.

Target audience: Pneumologists, GPs, and pneumologists with an interest in sleep medicine and clinical research.

Chairs: O.-C. Burghuber (Vienna, Austria), P. Levy (Grenoble, France)

- 14:45 COPD and OSA: the ultimate lethal combination for the cardiovascular system
A. Valipour (Vienna, Austria)
- 15:15 COPD and OSA: role of the autonomic nervous system
S. Andreas (Immenhausen, Germany)
- 15:45 Cardiovascular risk factors: current treatment strategies shaped for the pneumologist
D. Newby (Edinburgh, United Kingdom)
- 16:15 Treating the overlap syndrome in clinical practice
M. Machado (Sao Paulo, Brazil)

14:45 - 16:45

Symposium: An ERS/ELF joint symposium "New tools to assess improvement in respiratory patients: capturing the patient's perspective"

Aims: The aim of this symposium is to provide insight into the design and proper use of patient-reported outcomes (PRO).

Target audience: Pulmonologists, nurses, respiratory therapists, clinical researchers, research fellows, physiotherapists and industry.

Chairs: N. Kline Leidy (Bethesda, United States of America), T. Troosters (Leuven, Belgium)

- 14:45 From kitchen table questionnaires to valid PRO: how PRO's can provide insight in clinical events, the EXACT-PRO example
I. Wiklund (London, United Kingdom)
- 15:15 How do regulatory authorities feel about "PRO"?
Speaker to be confirmed
- 15:45 The patient on the drawing board: the example of PROactive, capturing physical activity
F. Dobbels (Leuven, Belgium)
- 16:15 A practical guide to the validation PRO tools on patients and numbers: the example of the COPD Assessment Tool (CAT)
P. Jones (London, United Kingdom)

14:45 - 16:45

Symposium: Viral respiratory disease in preschool children

Aims: The aim of this symposium is to get more insight on:

- the role of viral respiratory infections in otherwise healthy children and in children with chronic respiratory disease;
- the influence of viral infection on the innate immunity and immune responses in children with asthma and cystic fibrosis;
- the relationship between vitamin D status and susceptibility for viral infection;
- the therapeutic options for viral respiratory infections.

Target audience: Paediatric pulmonologists, general physicians, clinicians and microbiologists.

Chairs: M. Pijnenburg (Rotterdam, The Netherlands), F. De Baets (Ghent, Belgium)

- 14:45 Epidemiology of viral respiratory infection in children
M. Van Der Zalm (Utrecht, The Netherlands)
- 15:15 Why do viral respiratory infections cause greater morbidity in children with asthma than in healthy children?
S. L. Johnston (London, United Kingdom)
- 15:45 Vitamin D, host defense and viral infection
V. Walker (Los Angeles, United States of America)
- 16:15 How to prevent and treat acute viral bronchiolitis in children?
C. Wainwright (Brisbane, Australia)

14:45 - 16:45

Symposium: Autoimmunity in airways disease**Aims:** The aims of this symposium are:

- to appreciate the clinical evidence for a role for an autoimmune component in patients with airways disease;
- to understand the cellular and molecular pathways that drive autoimmunity and tolerance to self proteins and how this may be defective in COPD, for example;
- to obtain an overview as to the potential for new therapeutic approaches in patients with an autoimmune component to their disease.

Target audience: Researchers, clinical scientists and clinicians with an interest in immune mechanisms in airways disease.**Chairs:** G. Anderson (Parkville, Australia), M. Cosio (Padova, Italy)

- 14:45 Evidence for auto-antibodies in airways disease
H. Kerstjens (Groningen, The Netherlands)
- 15:15 IL-17 and other mediators in autoimmune responses
A. Van Oosterhout (Groningen, The Netherlands)
- 15:45 Modified self proteins as neo-antigens in COPD
P. Kirkham (London, United Kingdom)
- 16:15 Outlook: what will the future bring?
G. Joos (Ghent, Belgium)

14:45 - 16:45

Symposium: Reclassification of idiopathic interstitial pneumonias

Aims: The audience will gain knowledge of the impending reclassification of the idiopathic interstitial pneumonias (IIPs). The deficiencies in the 2002 classification will be addressed, especially the problem of NSIP (which was granted provisional clinical status in 2002). Histological, radiological and clinical aspects of the detailed classification will be addressed. The individual IIPs will be discussed with reference to a pragmatic disease behaviour/treatment strategy classification, applicable to interstitial lung disease in general. Those attending the session will increase their understanding of the thinking behind the proposed reclassification of the IIPs, and in doing so, they will apply classification more accurately in clinical practice, and have a better understanding of the underlying context of publications in this field. The audience will also take away a strong sense of the importance of multidisciplinary evaluation of the IIPs – an approach that is increasingly taking hold in regional centres throughout Europe. Managing patients with interstitial lung disease is one of the most difficult problems faced by respiratory physicians. The audience will learn how to apply the disease behaviour classification to manage challenging cases that are difficult to classify using the traditional approach.

Target audience: Clinicians, radiologists and pathologists.**Chairs:** U. Costabel (Essen, Germany), J. Ryu (Rochester, United States of America)

- 14:45 Introduction to classification
W. Travis (New York, United States of America)
- 15:15 A pragmatic clinical classification for interstitial lung disease
A. Wells (London, United Kingdom)
- 15:45 Multidisciplinary diagnosis and management: implications of the reclassification
T. King (San Francisco, United States of America)
- 16:15 Idiopathic interstitial pneumonias: molecular considerations
B. Crestani (Paris, France)

EVENING SYMPOSIA 17.15- 19.15**Predicting and Preventing Future Risk in COPD**

Organised by Takeda Pharmaceuticals International

Innovation for individualisation: Applying the science to the patient

Organised by GlaxoSmithKline

Balancing benefit and risk: new developments in the treatment of PAH

Organised by Novartis Pharma AG

Pneumonias in obstructive lung disease

Organised by AstraZeneca

Combination bronchodilators: the preferred treatment for COPD?

Organised by Boehringer Ingelheim

“Is it good enough?” - A debate on treatment response in pulmonary arterial hypertension

Organised by Actelion

Managing patients with IPF in a new era

Organised by InterMune International AG

Lower Respiratory Tract Infections: managing patients at risk of poor outcomes

Organised by Bayer HealthCare Pharmaceuticals

Prevention of Exacerbations in COPD: Expanding Scope and Strategies

Organised by OM Pharma Ltd

Personalized medicine: treatment advances and the genetic medicine revolution

Organised by Vertex Pharmaceuticals

COPD and AATD - Why do we miss so many patients?

Organised by Grifols International SA

EVENING MINI SYMPOSIA 17.30- 19.00**PneumRx lung volume reduction coil**

Organised by PneumRx

**Optimal management of pulmonary arterial hypertension patients: Are we there yet?
A case-based approach**

Organised by Pfizer Ltd

08:30 - 10:30

Paediatric Grand Round - an interactive session

Aims: Paediatric cases with respiratory problems and typical and difficult clinical questions will be presented. The audience will be engaged in discussions about best clinical care and will receive an update in paediatric respiratory medicine.

Target audience: Paediatricians, but also other clinically active colleagues.

- 08:30 Problems with air leaks in a neonate
 09:00 A wheezing infant: a joy forever?
 09:30 A 13-year-old with a history of repeat cardiorespiratory arrests and rapid onset obesity in early childhood
 10:00 A 16-year-old CF patient with increasing cough and worsening exercise tolerance

08:30 - 10:30

Symposium: Treatment of tobacco dependence as a treatment of lung diseases

Aims: This symposium aims to show why and how to integrate tobacco cessation (or reduction) in the treatment of these diseases.

At the end of the symposium, the audience will know the benefit of why and how:

- to treat tobacco dependence in all patients with COPD and lung carcinoma;
- to organise preoperatively smoking cessation;
- dependence treatment is assessed in the intensive care unit.

Target audience: Chest physicians, clinicians, scientists, GPs and the public.

Chairs: C. Gratiou (Athens, Greece), G. Viegi (Pisa, Italy)

- 08:30 The treatment of tobacco dependence: an effective treatment for lung cancer
 P. Aveyard (Birmingham, United Kingdom)
 09:00 The treatment of tobacco dependence: an effective treatment for COPD
 T. Hering (Berlin, Germany)
 09:30 Perioperative smoking cessation and surgical morbidity
 P. Tonnesen (Gentofte, Denmark)
 10:00 Nicotine replacement therapy in ICU patients
 D. Journois (Paris, France)

08:30 - 10:30

Symposium: Fighting MDR- and XDR-TB in Europe: from programme results to research implementation

Aims: The aims of this symposium are to:

- get an update on the control and elimination efforts coordinated by WHO in Europe, in collaboration with ERS;
- describe the main results achieved by the EU-funded project TB-PAN-NET;
- discuss the results of a large research project aimed at analysing a cohort of MDR-TB cases in Europe;
- summarise the research priorities as defined by WHO following the results of several meta-analyses launched to inform the new MDR-TB guidelines.

Target audience: Clinicians, clinical scientists, immunologists, microbiologists, specialist nurses and public health specialists involved in tuberculosis control, surveillance, care and research.

Chairs: H. Kluge (Copenhagen, Denmark), G. B. Migliori (Tradate, Italy)

- 08:30 Control of MDR/XDR-TB and elimination of TB in Europe: status update
 M. Dara (Copenhagen, Denmark)
 09:00 Answering the research gaps on MDR-TB in Europe: the results of the FP7-funded TB-PANNET project
 D. Cirillo (Milan, Italy)
 09:30 Evaluation of the MDR-TB cohort in Europe
 G. Guenther (Borstel, Germany)
 10:00 The global WHO priorities on TB research
 D. Falzon (Geneva, Switzerland)

08:30 - 10:30

Symposium: Lung transplantation in 2012: where are we?

Aims: The aim of this symposium is to provide a clear update on current indications for transplantation (who to refer) and expected outcome after transplantation.

Target audience: Pulmonologists, thoracic surgeons.

Chairs: A. Boehler (Zurich, Switzerland), G. Verleden (Leuven, Belgium)

- 08:30 Current outcome after lung transplantation
A. Fisher (Newcastle-Upon-Tyne, United Kingdom)
- 09:00 How far can we push the limits for a lung transplant candidate?
J. Gottlieb (Hannover, Germany)
- 09:30 Thoracic surgery in a potential lung transplant candidate: what is (im)possible?
G. Massard (Strasbourg, France)
- 10:00 Immunosuppression for the non-transplant physician: what should you know?
M. Iversen (Copenhagen, Denmark)

08:30 - 10:30

Symposium: Treatment of paediatric sleep-disordered breathing in special populations

Aims: The Speakers will review the latest advances in the treatment of sleep-disordered breathing in specific subpopulations in children. The conditions covered will include obesity, Down syndrome, neuromuscular disease and residual obstructive sleep apnoea after adenotonsillectomy. The presentations will discuss the benefits of surgical treatments, pharmacological treatments, non-pharmacological options including weight loss and noninvasive ventilation.

Target audience: Paediatricians, ear, nose and throat specialists, GPs, pneumologists with an interest in sleep medicine and sleep laboratory technicians.

Chairs: A. Kaditis (Piraeus, Greece), H. Trang (Paris, France)

- 08:30 Treatment of OSA in obese children: a “big” issue
S. Verhulst (Wilrijk, Belgium)
- 09:00 NIV in children with progressive neuromuscular disorders: an update
B. Fauroux (Paris, France)
- 09:30 Treatment options for sleep apnoea in children with Down syndrome
R. Amin (Cincinnati, United States of America)
- 10:00 Residual OSA after adenotonsillectomy: what's next?
M. Villa (Rome, Italy)

08:30 - 10:30

Symposium: Are neutrophils a suitable target in severe asthma?

Aims: The audience will improve their knowledge concerning the importance of neutrophils in asthma and the mechanisms of this type of inflammation with regard to newly identified T-cell populations (Th17).

Target audience: Clinicians and basic researchers involved in asthma care and research.

Chairs: G. Anderson (Parkville, Australia), A. Magnan (Nantes, France)

- 08:30 Th17 cells, neutrophils and airways hyperresponsiveness
M. Wills-Karp (Cincinnati, United States of America)
- 09:00 The role of neutrophils in severe asthma
R. Djukanovic (Southampton, United Kingdom)
- 09:30 Targeting neutrophils in asthma: a strategy shared with COPD?
E. Sapey (Worcester, United Kingdom)
- 10:00 Neutrophils and eosinophils trafficking in the lung
E. Chilvers (Cambridge, United Kingdom)

10:45 - 12:45

Hot Topic: The global burden of disease**Aims:** At the end of this session the audience will have gained knowledge in:

- the overall approach to assessing the global burden of disease in this context, and the assessment of disability adjusted life years;
- the current findings on the global burden of COPD and asthma;
- the current findings on the global burden of pneumoconiosis and interstitial lung disease;
- and the current information needed to enhance our understanding of the global burden of respiratory disease.

Target audience: Lung/respiratory and paediatric clinicians, GPs and community medicine workers, epidemiologists, occupational physicians and allied health professionals, nurses, health educators and researchers.

- 10:45 The history of the global burden of disease projects and how it works
 11:15 The global burden of asthma and COPD
 11:45 The global burden of pneumoconiosis and interstitial lung disease
 12:15 Getting better data to measure the burden of respiratory disease and influence health and public health policy

10:45 - 12:45

Symposium: Antenatal origins of chronic respiratory disease: putting the fetal origins hypothesis to the test**Aims:** The audience will gain an understanding of how and when antenatal factors influence fetal growth and how this is related to later respiratory outcomes.**Target audience:** Clinicians working in adult and paediatric respiratory services, epidemiologists and public health officers.**Chairs:** U. Frey (Basel, Switzerland), S. Shaheen (London, United Kingdom)

- 10:45 Might it all be determined before birth?
 P. Le Souef (Perth, Australia)
 11:15 The fetal origins hypothesis with a focus on respiratory outcomes
 K. Pike (Southampton, United Kingdom)
 11:45 Fetal growth, genes and environment
 C. Almqvist Malmros (Stockholm, Sweden)
 12:15 Antenatal fetal size and growth trajectory and respiratory outcomes in childhood
 S. Turner (Aberdeen, United Kingdom)

10:45 - 12:45

Symposium: Advances in chronic respiratory failure in COPD: now out of its infancy**Aims:** The aims of this symposium are to elucidate the current understanding for chronic respiratory failure in COPD patients and more specifically:

- to provide an overview on modern possibilities of rehabilitation of most severe COPD patients;
- to emphasise the increasing evidence to support the use of high-intensity positive pressure ventilation in chronic hypercapnic COPD patients;
- to highlight the modern view of subjective perception of chronic respiratory failure and, in this regard, to discuss the current concept of quality of life in these patients;
- to provide insight in the taboo subject of the circumstances of how these patients die.

Target audience: Pulmonary physicians, sleep physicians, intensivists and respiratory therapists.**Chairs:** S. Nava (Bologna, Italy), M. A. Spruit (Horn, The Netherlands)

- 10:45 Rehabilitation for advanced COPD patients: evidence and future directions
 S. Singh (Leicester, United Kingdom)
 11:15 High-intensity noninvasive positive pressure ventilation for COPD: it works!
 W. Windisch (Köln, Germany)
 11:45 Reduced quality of life in severe COPD: how to assess and how to handle?
 P. Jones (London, United Kingdom)
 12:15 How do patients with COPD and chronic respiratory failure die and what can we do?
 M. Vitacca (Lumezzane, Italy)

10:45 - 12:45

Symposium: Endo meets obstruction: the new endoscopic treatment options for obstructive lung diseases

Aims: During this symposium, based on the published literature, the techniques will be described and possible clinical algorithms will be presented and discussed.

Target audience: Clinicians, pulmonologists, surgeons, oncologists, GPs, residents and fellows.

Chairs: S. Gasparini (Ancona, Italy), C. Vogelmeier (Marburg, Germany)

- 10:45 Bronchial thermoplasty: an option for treating asthma?
P. Shah (London, United Kingdom)
- 11:15 The critical statement of the asthma expert
N. Thomson (Glasgow, United Kingdom)
- 11:45 Endoscopic lung volume reduction
F. Herth (Heidelberg, Germany)
- 12:15 Endoscopic lung volume reduction: the critical review of the COPD expert
P. M. A. Calverley (Liverpool, United Kingdom)

10:45 - 12:45

Symposium: Supportive and palliative care in the management of the patient with a thoracic malignancy

Aims: The aim of this symposium is to improve the supportive care delivered to cancer patients, allowing better delivering of chemotherapy, optimal control of symptoms, treatment of complications causing respiratory failure and adequate management of advanced disease.

Target audience: Chest physicians, oncologists and nurses dealing with the daily management of patients with thoracic malignancies.

Chairs: B. Grigoriu (Iasi, Romania), A.-P. Meert (Brussels, Belgium)

- 10:45 Haematological support by growth factors
T. Berghmans (Brussels, Belgium)
- 11:15 Pain management
C. Peeters-Asdourian (Boston, United States of America)
- 11:45 Pleural and pericardial effusion control
A. Scherpereel (Lille, France)
- 12:15 The role of palliative care
N. Schoenfeld (Berlin, Germany)

10:45 - 12:45

Symposium: Functional pulmonary imaging for COPD phenotyping

Aims: The aim of this symposium is to explain the methods and to put them into clinical perspective.

Target audience: Clinicians and researchers.

Chairs: A. Aliverti (Milan, Italy), P. Laveneziana (Paris, France)

- 10:45 Lung perfusion measured using magnetic resonance imaging
G. Prisk (La Jolla, United States of America)
- 11:15 Image-based modelling of lung structure and function
W. De Backer (Antwerp, Belgium)
- 11:45 Imaging of lung function using hyperpolarised helium
M. Kirby (London, Canada)
- 12:15 Imaging phenotypes of COPD
G. Washko (Boston, United States of America)

10:45 - 12:45

Symposium: Acute lung injury: challenging old paradigms

Aims: The aim of this symposium is to provide fundamental and clinically relevant knowledge about ARDS and discuss novel strategies which are required to develop new therapeutic options.

Target audience: Clinicians and scientists interested in acute lung injury and ARDS.

Chairs: J. Hamacher (Bern, Switzerland), T. Martin (Seattle, United States of America)

- 10:45 Is apoptosis really important?
G. Matute-Bello (Seattle, United States of America)
- 11:15 Why are so many treatments effective experimentally? A systems biology approach
J. Garcia (Chicago, United States of America)
- 11:45 Inflammation and parainflammatoin
S. Uhlig (Aachen, Germany)
- 12:15 What happens beyond the first day of the disease?
J. Vincent (Brussels, Belgium)

14:45 - 16:45

Ethics Grand Round - an interactive session

Aims: Awareness of specific ethical question of actual problems that are relevant in patients treatment supporting decisions in daily practice. It will influence the critical reading of large trials, looking to the unanswered questions. For those who set up trials and are involved in funding it will be helpful to consider the definition of benefit with respect to economics and ethics as discussed in the session. The audience can participate by electronic voting to check their decision in all presentations.

Target audience: Clinicians and clinical researchers and consultants of the pharmaceutical industry.

- 14:45 The choice of recipient during lung allocation in Europe and in the USA
- 15:15 Domiciliary ventilation: living and dying under a machine?
- 15:45 LD-CT lung cancer screening: the diagnostic pressure on medical doctors and the quality of life of their patients
- 16:15 Palliative care or standard chemotherapy in lung cancer patients?

14:45 - 16:45

Symposium: When the whole body is affected: comorbidity and COPD

Aims: The aim of this symposium is to provide an update on the prevalence, pathophysiology, impact and practical management of COPD patients with comorbidities.

Target audience: Clinicians, GPs and nurses.

Chairs: N. Chavannes (Leiden, The Netherlands), C. Janson (Uppsala, Sweden)

- 14:45 What are the main comorbidities in COPD?
J. Soriano (Bunyola, Spain)
- 15:15 What is the reason for comorbidities in COPD: pathophysiology?
E. F. M. Wouters (Maastricht, The Netherlands)
- 15:45 What is the impact of comorbidity on quality of life and prognosis?
A. Lindberg (Lulea, Sweden)
- 16:15 How to manage COPD patients with more than one disease in a primary care setting
H. Pinnock (Edinburgh, United Kingdom)

14:45 - 15:05

Maurizio Vignola Award for Innovation in Pneumology Ceremony (supported by Chiesi Foundation)

15:05 - 16:45

followed by Clinical Year in Review I

Aims: This session will offer the possibility to review four topics of paramount interest for clinicians and fellows in training. This will highlight the new and emerging clinical concepts in the management of respiratory related diseases and conditions.

Target audience: Clinicians, surgeons, allied health professionals involved in patient care, and trainees.

- 15:05 Non-small cell lung cancer
- 15:30 Tuberculosis
- 15:55 Smoking cessation
- 16:20 Cystic fibrosis

14:45 - 16:45

Symposium: Improving adherence to maintenance medication in asthma: new tools for the clinician**Aims:** The aims of this symposium are to:

- review data on adherence in relation to asthma control in adults and children;
- present an overview of data on the impact of patient's illness and medication beliefs on adherence to maintenance medication in asthma;
- discuss how clinicians can improve adherence to maintenance medication in children and adults with asthma, by specific communication techniques in follow-up visits.

Target audience: Paediatricians, pulmonologists, GPs and asthma nurses.**Chairs:** G. Hedlin (Stockholm, Sweden), M. Fletcher (Warwick, United Kingdom)

- 14:45 Adherence to maintenance medication in adult and paediatric asthma: facts and figures, myths and misconceptions
L. Heaney (Belfast, United Kingdom)
- 15:15 Illness and medication beliefs: key determinants of adherence to maintenance medication in chronic asthma
A. Kaptein (Leiden, The Netherlands)
- 15:45 The patient's perspective and shared decision making
D. Supple (Brighton, United Kingdom)
- 16:15 Organising your asthma clinic: how to optimise adherence to maintenance therapy
P. L. P. Brand (Zwolle, The Netherlands)

14:45 - 16:45

Symposium: Nanosafety: human health risk assessment

Aims: The audience will be updated on current and future European research initiatives/strategies in the area. It involves multidisciplinary research and the aim is to highlight how this is being managed in the global effort to address the issues surrounding the ever-increasing, everyday use of engineered nanomaterials. The audience will then hear about studies of the pulmonary effects of some of these materials, specifically on the immune system and inflammatory, genotoxic and carcinogenic effects.

Target audience: This session will be of interest to clinicians and basic scientists who are interested in bionano-interactions in the lung.**Chairs:** P. Gehr (Bern, Switzerland), T. Tetley (London, United Kingdom)

- 14:45 Bionanosciences and the lung: a European perspective
K. Dawson (Dublin, Ireland)
- 15:15 Modulation of T-cell responses by nanoparticles
C. Von Garnier (Bern, Switzerland)
- 15:45 Genotoxic effects of nanoparticles: new perspectives
R. Schins (Dusseldorf, Germany)
- 16:15 Nanoparticles for cancer therapy
A. Jordan (Berlin, Germany)

14:45 - 16:45

Hot Topic: The bacterial microbiota: implications for health and disease - joint session with World Allergy Organisation

Aims: An understanding of the latest findings concerning the microbiome and its implications for lung diseases. A critical perspective of whether the microbiome should be considered in clinical practice and basic research.

Target audience: Clinicians and basic researchers.

- 14:45 Microbiome in small airways in asthma
- 15:15 Significance of the microbiome in obstructive lung disease: where to from here?
- 15:45 Shaping of pulmonary inflammation by the lung microbiome
- 16:15 The consequences of microbiome and pathogen dynamics for chronic lung diseases

EVENING SYMPOSIA 17.15- 19.15

New strategies, meaningful outcomes, and therapeutic options for COPD

Organised by Novartis Pharma AG

Anticholinergics in Asthma: Could They Impact Exacerbations?

Organised by Boehringer Ingelheim

Seeing COPD from the patient's perspective

Organised by Ammiral S.A.

Continuity of care in asthma and COPD: Do we understand the future risks?

Organised by AstraZeneca

Idiopathic pulmonary fibrosis – challenges and perspectives in a rare disease

Organised by Boehringer Ingelheim

Small airways: clinical implications

Organised by Takeda Pharmaceuticals International

Changing the pneumococcal vaccination paradigm

Organised by Pfizer International Operations

EVENING MINI SYMPOSIA 17.30- 19.00

Exhaled Nitric Oxide in Clinical Practice

Organised by Aerocrine AB

08:30 - 10:30

Respiratory infectious diseases Grand Round - an interactive session

Aims: This interactive session will demonstrate experts approach to difficult case management and application of new guidelines into clinical practice.

Target audience: Clinicians, surgeons, paediatricians, critical care specialists, fellows and nurses.

- 08:30 Severe respiratory infection: when is ICU mandatory ?
 09:00 An 11 year old girl with asthma, hoarse voice, regular cough and no clubbing
 09:30 Pseudomonas before and after lung transplantation: to treat or not to treat?
 10:00 Double edge sword: antibiotics in the prevention and treatment of COPD exacerbation

08:30 - 10:30

Paediatric Year in Review

Aims: The audience will receive an update and overview on the topics that will be presented by experienced clinicians.

Target audience: Paediatricians but also other clinically active clinicians, GPs and health professionals.

- 08:30 Clinical lung function tests in young children
 09:00 Paediatric asthma and allergy
 09:30 Sleep, respiratory failure and mechanical ventilation
 10:00 Intensive Care

08:30 - 10:30

Symposium: Genetics and genomics in asthma and COPD: prediction and personalised medicine

Aims: The audience will take away from this symposium an understanding of:

- the (im)possibility of using genomics and genetics to predict the efficacy of asthma/COPD treatment - the applicability of personalised medicine;
- the predictive value of genetic profiling from a methodological perspective;
- issues around psychological, behavioural and ethical aspects of genetic testing;
- the value of genetics compared to phenotypic and environmental factors in asthma and COPD;
- how current knowledge on primarily hereditary risk factors for asthma and other lung diseases improve prevention, treatment and prognosis of asthma.

Target audience: Clinicians, epidemiologists, researchers and health policy makers.

Chairs: H. M. Boezen (Groningen, The Netherlands), V. Schluenssen (Aarhus, Denmark)

- 08:30 Predictive and personalised medicine for asthma using genomics
 S. Weiss (Boston, United States of America)
 09:00 Genome-based risk prediction of asthma and COPD: applicability and psychological issues
 C. Janssens (Rotterdam, The Netherlands)
 09:30 Genotype, phenotype and the environment in respiratory diseases: what contributes the most?
 I. Wouters (Utrecht, The Netherlands)
 10:00 How does current knowledge on primarily hereditary risk factors for asthma and other lung diseases improve prevention, treatment and prognosis?
 D. S. Postma (Groningen, The Netherlands)

08:30 - 08:50

ERS Award for Rare Pulmonary Disease Ceremony (supported by GlaxoSmithKline)

08:50 - 10:30

followed by symposium "Update on orphan lung diseases"

Aims: The aim of this symposium is to set out current approaches of the diagnostic and novel treatment modalities of orphan lung diseases with recent advances, with practical consequences and impacts for chest physicians and radiologists, in a comprehensive and global session.

Target audience: Clinicians, chest physicians and private and hospital-based radiologists.

Chairs: V. Poletti (Forli, Italy), C. Robalo Cordeiro (Coimbra, Portugal)

- 08:50 Multiple cystic lung disease: the three big causes and the diagnostic approach
 J-F. Cordier (Lyon, France)
 09:15 Orphan tracheopathies: from systemic to multidisciplinary local management
 J. Ryu (Rochester, United States of America)

- 09:40 Pulmonary vascular complications of hereditary hemorrhagic telangiectasia
V. Cottin (Lyon, France)
- 10:05 Pulmonary alveolar proteinosis: from bench to bedside
B. Trapnell (Cincinnati, United States of America)

08:30 - 10:30

Symposium: Non-antibiotic effects of macrolides in lung disease

Aims: The aim of this symposium is to inform clinicians about the new developments in the use of neomacrolides for lung diseases.

Target audience: Clinicians, pulmonologists, paediatricians, thoracic surgeons and infectiologists.

Chairs: I. M. Adcock (London, United Kingdom), A. Fisher (Newcastle-Upon-Tyne, United Kingdom)

- 08:30 Neomacrolides in cystic fibrosis
A. Bush (London, United Kingdom)
- 09:00 Macrolides in the prevention of COPD exacerbations
J. Wedzicha (London, United Kingdom)
- 09:30 Neomacrolides in the treatment of asthma
G. Brusselle (Ghent, Belgium)
- 10:00 The role of azithromycin after lung transplantation
G. Verleden (Leuven, Belgium)

08:30 - 10:30

Symposium: Gender-related differences in pulmonary disease

Aims: The audience will learn:

- the extent of gender differences in asthma, cystic fibrosis, COPD and non-small cell lung cancer;
- the molecular basis of estrogen-related differences in cystic fibrosis;
- how genetic and environmental factors contribute to gender differences in lung disease;
- and the potential for gender-specific therapies to treat these diseases.

Target audience: Scientists, clinicians and pulmonary physicians.

Chairs: C. Greene (Dublin, Ireland), B. Melgert (Groningen, The Netherlands)

- 08:30 Asthma: why gender and age are important?
C. Svanes (Bergen, Norway)
- 09:00 The cystic fibrosis gender gap: past observations, present understanding and future directions
S. Chotirmall (Dublin, Ireland)
- 09:30 Gender differences in COPD: are women more susceptible to smoking effects than men?
I. Sorheim (Bergen, Norway)
- 10:00 Cell gender and cell fate: a keystone in tumour growth?
W. Malorni (Rome, Italy)

10:45 - 11:05

Research Award on Idiopathic Pulmonary Fibrosis Ceremony (supported by InterMune)

11:05 - 12:45

Followed by Clinical Grand Round - an interactive session

Aims: This grand round will discuss important topics in general pulmonology practice by showing four interesting cases with distinct problems of diagnosis and treatment. The case presentation given by experts will follow an interactive format and include an update of the most recent literature.

Target audience: Clinicians and trainees interested in clinical practice and in the clinical reasoning process in an up-to-date methodology.

- 11:05 Diffuse pulmonary infiltrates with myalgia: reversible or not?
- 11:30 Unexplained isolated weight loss in a 40-year-old Bangladesh man
- 11:55 Acute respiratory failure in a young, neat and tidy adult
- 12:20 A 69-year-old male with progressive dyspnoea and dysarthria

10:45 - 12:45

Symposium: The promise of new drugs for treating asthma and COPD

Aims: The aim of this symposium is to learn about some of the new drugs in development and the new approaches to treating severe asthma and COPD.

Target audience: Physicians, scientists and pharmaceutical companies.

Chairs: G. Caramori (Ferrara, Italy), C. Vogelmeier (Marburg, Germany)

- 10:45 New bronchodilators
M. Cazzola (Rome, Italy)
- 11:15 Biologics for the treatment of asthma and COPD
G. Brusselle (Ghent, Belgium)
- 11:45 Kinase inhibitors
I. M. Adcock (London, United Kingdom)
- 12:15 Reversing glucocorticoid resistance as a new therapeutic strategy
P. J. Barnes (London, United Kingdom)

10:45 - 12:45

Symposium: Modelling respiratory infections: is it the future or the present?

Aims: The aim of this symposium is to understand the mechanisms of colonisation and infection of the lower respiratory tract and gain insight into the new research lines of modelling respiratory infections.

Target audience: Clinicians, basic researchers and microbiologists.

Chairs: W. Boersma (Alkmaar, The Netherlands), S. Sethi (Buffalo, United States of America)

- 10:45 Modelling exacerbations of COPD
S. L. Johnston (London, United Kingdom)
- 11:15 Animal models of bronchial and parenchymal lung infection
G. Li Bassi (Barcelona, Spain)
- 11:45 Modelling asthma exacerbations with rhinovirus
J. Beale (London, United Kingdom)
- 12:15 Modelling respiratory infections: future or present?
A. Papi (Ferrara, Italy)

10:45 - 12:45

Symposium: COPD in non-smokers: an important neglected disease

Aims: The aims of this symposium are:

- to understand the size of the problem;
- to appreciate the causes of non-smoking COPD;
- to understand the mechanisms of non-smoking COPD;
- to be aware of the need for research in this area.

Target audience: This symposium will be of interest to all respiratory physicians, epidemiologists and researchers.

Chairs: T. Sigsgaard (Aarhus, Denmark), J. Soriano (Bunyola, Spain)

- 10:45 The global problem of non-smoking COPD
P. Burney (London, United Kingdom)
- 11:15 Biomass fuels as a cause of COPD
S. Salvi (Pune, India)
- 11:45 Asthma as a cause of COPD
I. Pavord (Leicester, United Kingdom)
- 12:15 The need for more research on non-smoking causes of COPD
R. A. Stockley (Birmingham, United Kingdom)

14:45 - 15:05

Ceremony for Pulmonary Arterial Hypertension Award (supported by Actelion)

15:05 - 16:45

followed by Clinical Year in Review II

Aims: This session will offer the possibility to review four topics of paramount interest for clinicians and fellows in training. This will highlight the new and emerging clinical concepts in the management of respiratory-related diseases and conditions.

Target audience: Clinicians, surgeons, allied health professionals involved in patient care, and trainees.

- 15:05 Asthma
- 15:30 Management of sepsis
- 15:55 Interstitial lung disease
- 16:20 Pulmonary hypertension

14:45 - 16:45

Symposium: Good quality clinical recommendations for thoracic malignancy management in Europe

Aims: The aim of this symposium is to obtain information about the health organisation and facilities for thoracic malignancies in various European countries, to obtain practical information about the literature on quality assessment in thoracic oncology and to identify which of the available guidelines are good.

Target audience: Any chest physician, oncologist, surgeon, radiotherapist or nurse dealing with patients with thoracic malignancies.

Chairs: N. Schoenfeld (Berlin, Germany), J-P. Sculier (Brussels, Belgium)

- 14:45 Published literature and guidelines in thoracic oncology: what is worth reading?
M. Paesmans (Brussels, Belgium)
- 15:15 National and local care in thoracic oncology: does Europe speak the same language?
A. Rich (Nottingham, United Kingdom)
- 15:45 Improving tumour documentation in thoracic oncology: what can we learn from each other?
D. Baldwin (Nottingham, United Kingdom)
- 16:15 Quality management in thoracic oncology: how do patients and clinicians benefit?
T. Blum (Berlin, Germany)

14:45 - 16:45

Symposium: Impact of traffic-related pollution on children's lungs

Aims: After attending this symposium, the audience will have an up to date understanding of the detrimental effects of exposure to traffic-related pollutants on children's lungs and an increased understanding of the mechanisms underlying these observations.

Target audience: Respiratory clinicians and trainees, epidemiologists, exposure scientists, cell biologists, geneticists.

Chairs: E. Eber (Graz, Austria), K. Lodrup Carlsen (Oslo, Norway)

- 14:45 What does the epidemiology tell us?
U. Gehring (Utrecht, The Netherlands)
- 15:15 Genetic susceptibility and epigenetic mechanisms
M. Kabesch (Hannover, Germany)
- 15:45 Pulmonary defense systems and inflammatory mechanisms
P. Sly (Herston, Australia)
- 16:15 Exposure assessment and measuring effects on the lungs
J. Grigg (London, United Kingdom)

14:45 - 15:05

ERS Romain Pauwels Research Award Ceremony (supported by GlaxoSmithKline)

15:05 - 16:45

followed by the Hot Topic "The nerves are back!"

Aims: The session will inform the audience about the crucial role of airway nerves in the pathophysiology of asthma and COPD and provide an update on recent exciting pharmacological developments to treat neuronal dysfunction in these diseases.**Target audience:** Clinicians, researchers and pharmacologists.

- 15:05 The crucial role of airway nerves in asthma and COPD
- 15:30 Targeting neuropeptides: from antiemetics to bronchodilators?
- 15:55 Targeting sensory nerves: are TRPA1 antagonists the magic bullet?
- 16:20 The nerves are back in respiratory pharmacology: how will that change clinical practice?

EVENING SYMPOSIA

17.15- 19.15

Small airways involvement in respiratory diseases: a paradigm shift in diagnosis and management

Organised by Chiesi Farmaceutici Spa

From early diagnosis to long-term management of PAH patients

Organised by GlaxoSmithKline

EVENING EXPERT FORUM

17.30 - 19.00

It's just a matter of time: a case-based forum for physicians managing PAH

Organised by United Therapeutics

08:30 - 10:30

Symposium: New ATS/ERS recommendations for bronchoprovocation challenge testing

Aims: Bronchial challenge tests are one of the main diagnostic tests for asthma. There is, however, a lack of standardisation in this field (e.g. which nebuliser/protocols to use when performing a metacholine-challenge test). Meanwhile, new development (like mannitol) are already being used in clinical practice but are not included in the existing guidelines. This Task Force will present up-to-date guidelines in the field of direct and indirect bronchial challenge testing.

Target audience: Clinicians and respiratory technicians.

Chairs: B. Culver (Washington, United States of America), F. De Jongh (Enschede, The Netherlands)

- 08:30 Exercise, isocapnoeic hyperpnoea and cold air challenge test
K-H. Carlsen (Oslo, Norway)
- 08:54 Direct bronchial challenge test
A. Coates (Toronto, Canada)
- 09:18 Mannitol: a new development in challenge testing
J. D. Leuppi (Basel, Switzerland)
- 09:42 Allergen challenge in clinical asthma research
Z. Diamant (Lund, Sweden)
- 10:06 Indication, interpretation and clinical utility of bronchoprovocation testing
P. Enright (Tucson, United States of America)

08:30 - 10:30

Symposium: Update on bronchiectasis

Aims: The audience will obtain information on new immunological concepts with regard to epithelial mesenchymal transition, microbosome/immunological interactions, potential impact of reflux disease. In addition, an update will be provided on current antibiotic use (inhalation, etc.), immunomodulatory therapy, when to treat surgically and when to consider lung transplantation.

Target audience: Pulmonary physicians, paediatricians and thoracic surgeons.

Chairs: A. End (Vienna, Austria), J. Lordan (Newcastle-Upon-Tyne, United Kingdom)

- 08:30 New insights into pathogenesis of bronchiectasis
C. Ward (Newcastle-Upon-Tyne, United Kingdom)
- 09:00 What is the optimal medical therapy?
R. Wilson (London, United Kingdom)
- 09:30 Indications for surgical treatment in limited bronchiectasis
D. Subotic (Belgrade, Republic of Serbia)
- 10:00 Lung transplantation for diffuse bronchiectasis
M. Iversen (Copenhagen, Denmark)

08:30 - 08:50

ERS COPD Research Award Ceremony (supported by Boehringer Ingelheim)

08:50 - 10:30

followed by the Hot Topic "It takes two to tango: innate and adaptive immunity in COPD"

Aims: After the session the audience will understand the abnormalities in the functioning of the innate as well as the adaptive part of the immune system in the lungs of COPD patients, the interactions between the two and the way these deviations are thought to contribute to the pathophysiology of COPD.

Target audience: Clinicians caring for COPD patients and researchers in the field of COPD.

- 08:50 Macrophage heterogeneity in COPD
- 09:15 Dendritic cells as key players in COPD pathogenesis
- 09:40 Adaptive immune system in COPD: auto-immunity or bystander?
- 10:05 T-cells in COPD: harmful or protective?

08:30 - 10:30

Symposium: Infection control of respiratory pathogens

Aims: The audience will become familiar with the risk of transmission of respiratory pathogens under different circumstances and with optimal infection control policies. These include influenza, emerging multidrug-resistant bacteria in the ICU and the transmission of Mycobacterium tuberculosis. In addition, the concept of antibiotic stewardship will be presented.

Target audience: Respiratory specialists, nurses, emergency staff, allied respiratory professionals, GPs, infectious respiratory disease specialists, epidemiologists, disease transmission modellers, public health policy developers and decision makers.

Chairs: J. Zayas (Edmonton, Canada), C. Lange (Borstel, Germany)

- 08:30 Controlling the spread of MDR respiratory pathogens in the ICU
S. Ewig (Bochum, Germany)
- 09:00 Influenza viruses: risks and prevention of their transmission
A. Nicoll (Stockholm, Sweden)
- 09:30 Infection control: a priority to stop the nosocomial spread of MDR-/XDR-TB
C. Popa (Bucharest, Romania)
- 10:00 Antibiotic stewardship
S. Lemmen (Aachen, Germany)

08:30 - 10:30

Hot Topic: The updated ATS/ERS statement on pulmonary rehabilitation - update from the ATS/ERS Task Force

Aims: At the end of the session, the participant will be able to understand:

- the organisation of a state-of-the-art about pulmonary rehabilitation for patients with chronic respiratory disease;
- how to organise state-of-the-art pulmonary rehabilitation for patients with chronic respiratory disease;
- the patient-centered outcomes of pulmonary rehabilitation;
- the different interventions of pulmonary rehabilitation (exercise training, nutritional modulation, self-management strategies and psychosocial interventions);
- and the positive effects of pulmonary rehabilitation.

Target audience: Clinicians, trainees, fellows, physiotherapists, occupational therapists, psychologists, nutritionists, nurses, social workers, health care managers, insurance companies, lung function technicians, physiologists and health educators.

- 08:30 New definition of pulmonary rehabilitation
- 09:00 Exercise training, nutritional modulation and hormonal supplements during pulmonary rehabilitation
- 09:30 Behaviour challenge and collaborative self-management strategies during pulmonary rehabilitation
- 10:00 Patient-centred outcomes of pulmonary outcomes

10:45 - 12:45

Symposium: Exercise testing in PAH patients

Aims: The audience will gain state-of-the-art knowledge on the evidence supporting and contrasting the use of field and cardiopulmonary exercise testing as clinical, prognostic and research tools.

Target audience: Pulmonologist, respiratory physicians, exercise physiologists, researchers and clinicians, GPs, respiratory therapists and technicians interested in the use of field and cardiopulmonary exercise testing in clinical practice and research.

- 10:45 Exercise haemodynamics in PAH
- 11:15 Cardiopulmonary exercise testing in PAH
- 11:45 The clinical and prognostic evaluation of patients with PAH
- 12:15 Exercise testings in evaluating the effects of intervention in PAH

10:45 - 12:45

Symposium: New guidelines in respiratory infections

Aims: The decision of when and how to treat respiratory infections is often difficult. This is particularly complicated when it is unclear whether an isolated microorganism is really the causative agent of a disease, or not, and when resistant strains are isolated. This session provides a guideline for practicing physicians on how to deal with common clinical situations, based on the "state-of-the-art" guidelines on management of LRTI in the community, AE-COPD, CAP and TB.

Target audience: Respiratory clinicians, internal medicine and infectious disease specialists, family doctors, microbiologists, paediatricians, nurses and public health workers involved in care and control of respiratory infections.

- 10:45 Current guidelines on management of LRTI in the community
- 11:15 What's new in the management of CAP?
- 11:45 Recommendations for the rational use of antibiotics in AE-COPD
- 12:15 Rational use of new TB drugs in the EU

10:45 - 12:45

Symposium: Diagnosis and management of thymic malignancies: an update**Aims:** The symposium is designed to be both:

- a short refresher course on the diagnosis and management of thymic tumors but also increase awareness about the actual problems raised when managing thymoma, and an up-to-date presentation of current classification, diagnosis strategy and the most common issues in therapeutic management will be offered to participants.

Target audience: Respiratory physicians, surgeons and medical oncologists including those in training. Clinical and basic and researchers as well as epidemiologists involved in thymoma research.

Chairs: B. Grigoriu (Iasi, Romania), M. Lucchi (Pisa, Italy)

- 10:45 Thymic tumours: update on classification and prognostic factors
P. Stroebel (Mannheim, Germany)
- 11:15 Diagnostic work-up and staging of thymoma
E. Ruffini (Torino, Italy)
- 11:45 Strategy in initially resectable thymoma
P. Van Schil (Antwerp, Belgium)
- 12:15 Treatment options in non-resectable thymoma
N. Girard (Lyon, France)

10:45 - 12:45

Symposium: Contributing factors to pulmonary hypertension

Aims: Different aetiologies of pulmonary hypertension must be known in order to choose the appropriate treatment and to improve the quality of life of patients with pulmonary hypertension.

Target audience: Clinicians.

Chairs: R. Naeije (Brussels, Belgium), L. Nicod (Lausanne, Switzerland)

- 10:45 Genetics in pulmonary hypertension
R. Trembath (London, United Kingdom)
- 11:15 Role of Gremlin in pulmonary hypertension
S. Gaine (Dublin, Ireland)
- 11:45 Cardiac shunt in COPD as a cause of severe hypoxaemia: probably not so uncommon after all
A. Vonk Noordegraaf (Amsterdam, The Netherlands)
- 12:15 Pulmonary arterial hypertension in adults with congenital heart disease
S. Orfanos (Haidari, Greece)

10:45 - 12:45

Symposium: Unusual NIV applications for acute respiratory failure

Aims: The aim of this symposium is to illustrate possible new scenarios and applications for non-invasive respiratory support in areas where EBM is still lacking.

Target audience: Pulmonologists, intensivists, palliative care doctors, surgeons, respiratory therapists, nurses and technicians.

Chairs: W. Windisch (Köln, Germany), A. Carlucci (Milan, Italy)

- 10:45 CPAP outside the hospital: does it make sense?
D. Payen (Paris, France)
- 11:15 Non-invasive ventilation in severe acute asthma: still far from the truth
N. Hill (Providence, United States of America)
- 11:45 New technical developments in noninvasive respiratory support
P. Navalesi (Vercelli, Italy)
- 12:15 Non-invasive ventilation for pandemics: risky business?
S. Nava (Bologna, Italy)